

Please type a plus sign (+) inside this box ☐

Attorney Docket P0706P2C2D2
PATENT

CERTIFICATION UNDER 37 CFR 1.10

EL142012237US Express Mail Number

June 24, 1998: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Yvonne E. Carter

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

James Lee
William I. Wood

Title: **NUCLEIC ACIDS ENCODING PF4A RECEPTOR**

1. Type of Application

- ☐ This application is for an original, non-provisional application.
- ☐ This is a non-provisional application claiming priority to provisional application no. __, filed ____, the entire disclosure of which is hereby incorporated by reference.
- ☒ This is a ☐ continuation-in-part ☐ continuation ☒ divisional application of copending U.S. Serial Number 08/701,265, filed 22 August 1996, which is a continuation application of U.S. Serial No. 08/664,228, filed June 6, 1996, now abandoned, which is a continuation application of U.S. Serial No. 08/076,093, filed June 11, 1993, now U.S. Pat. No. 5,543,503, which is a continuation-in-part application of U.S. Serial No. 07/810,782, filed December 19, 1991, now abandoned, the entire disclosures of which applications are hereby incorporated by reference, and to which applications priority is claimed under 35 U.S. C §120.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)
(Non-provisional)**

88 pages of specification
2 pages of claims
1 page(s) of abstract
17 sheet(s) of drawings
☐ formal ☒ informal

JC526 U.S. PTO
09/104063
06/24/98

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

___ An executed declaration of the inventor(s) [] is enclosed [] will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

X A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)

___ A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)

___ An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.

(for cont./div.)

X The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

___ Cancel in this application original claims ___ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

X A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

___ Amend the specification by inserting before the first line the sentence:

--This is a

___ non-provisional application

___ continuation

___ divisional

___ continuation-in-part

of co-pending application(s)

___ Serial No. _____ filed on _____, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --

___ International Application _ filed on _ which designated the U.S., which application(s)

09404030-034098

is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--

_____ provisional application No. ___ filed ___, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--.

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$790.00
Total Claims	14	- 20 =	0	X \$22.00	\$0.00
Independent Claims	4	- 3 =	1	X \$82.00	\$82.00
_____ Multiple dependent claim(s), if any				+ \$270.00	\$790.00
Filing Fee Calculation					\$872.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$872.00. **A duplicate copy of this transmittal is enclosed.**

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☒ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☐ Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

*[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- _____ A petition, fee and/or response has been filed to extend the term in the pending prior application until _____
- _____ A copy of the petition for extension of time in the **prior** application is attached.

1364290 " E9040760

11. Correspondence Address:

X Address all future communications to:

GENENTECH, INC.
Attn: Richard B. Love
1 DNA Way
South San Francisco, CA 94080-4990
(650) 225-5530

Respectfully submitted,
GENENTECH, INC.

Date: June 24, 1998

By: Richard B. Love
Richard B. Love
Reg. No. 34,659

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5530
Fax: (650) 952-9881

064230" E3240760

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Rule 53(b) Divisional Application of Lee et al.</p> <p>Serial No.: 08/701,265</p> <p>Filed: 22 August 1996</p> <p>For: ANTIBODIES TO HUMAN PF4A RECEPTOR AND COMPOSITIONS THEREOF</p>	<p>Previous Group Art Unit: 1644 Previous Examiner: P. Nolan</p> <hr/> <p>CERTIFICATION UNDER 37 CFR 1.10 EL142012237US: Express Mail Number Date of Deposit: June 24, 1998</p> <p>I hereby certify that this Preliminary Amendment is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231</p> <p><i>[Signature]</i> Yvonne E. Carter</p>
--	--

PRELIMINARY AMENDMENT UNDER 37 C.F.R. §115**BOX SEQUENCE**

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In advance of examination of the above-identified application, which is a 37 C.F.R. §1.53(b) divisional application of U.S. Ser. No. 08/701,265 filed August 22, 1996, please enter the following amendment.

IN THE TITLE:

Please delete the title and insert therefor --NUCLEIC ACIDS ENCODING PF4A RECEPTOR--.

IN THE SPECIFICATION:

Please delete lines 12-15 on page 1 and insert therefor

--This is a divisional application of copending U.S. Serial No. 08/701,265 filed August 22, 1996, which is a continuation application of U.S. Serial No. 08/664,228 filed June 6, 1996, now abandoned, which is a continuation application of U.S. Serial No. 08/076,093 filed June 11, 1993, now U.S. Patent No. 5,543,503, which is a continuation-in-part application of U.S. Serial

No. 07/810,782 filed December 19, 1991, now abandoned, which is a continuation-in-part application of U.S. Serial No. 07/677,211 filed March 29, 1991, now abandoned to which applications priority is claimed under 35 U.S.C. §120.--

On page 5, lines 30-33, please delete "Figs. 2a-2c (SEQ ID NO. 1) (hereinafter referred to collectively as Fig. 2) depicts the amino acid and nucleotide sequences of the IL-8 receptor cDNA insert from clone pRK5B.il8rl.1" and insert therefor --Figs. 2a-2c (hereinafter referred to collectively as Fig. 2) depict the amino acid (SEQ ID NO. 2) and nucleotide (SEQ ID NO. 1) sequences of the IL-8 receptor cDNA insert from clone pRK5B.il8rl.1.--

On page 6, lines 22-26, please delete "Figs. 4 (SEQ ID NO.2) and 5 (SEQ ID NO.3) depict the DNA and an imputed polypeptide sequences for two additional PF4AR members identified by probing lambda libraries from a human monocyte-like cell line (HL-60) and human PBLs using a large fragment of the IL-8 receptor DNA." and insert therefor

--Figs. 4a-c (hereinafter collectively referred to as Fig. 4) depict the DNA sequence (SEQ ID NO.3) and an imputed polypeptide sequence (SEQ ID NO.4) for an additional chemokine superfamily receptor identified by probing lambda libraries from a human monocyte-like cell line (HL-60) and human PBLs using a large fragment of the IL-8 receptor DNA.

Figs. 5a-c (hereinafter collectively referred to as Fig. 5) depict the DNA sequence (SEQ ID NO. 5) and an imputed polypeptide sequence (SEQ ID NO.6) for yet another chemokine superfamily receptor identified by probing lambda libraries from a human monocyte-like cell line (HL-60) and human PBLs using a large fragment of the IL-8 receptor DNA.--

Please amend the specification by replacing the original Sequence Listing pages 78-88 with the attached revised Sequence Listing as pages 78-88.

IN THE CLAIMS:

Please cancel claims 1-19, without prejudice.

Please add the following claims:

--20. An isolated nucleic acid molecule encoding a platelet factor 4 superfamily receptor (PF4AR) polypeptide comprising a stretch of at least 10 contiguous amino acid residues selected from an extracellular region of a receptor polypeptide having the amino acid sequence of Fig. 4 (SEQ ID NO. 4).

21. The nucleic acid molecule of claim 20 wherein the extracellular region is the N-terminal extracellular region.

22. The nucleic acid molecule of claim 20 wherein the PF4AR polypeptide comprises an amino acid sequence spanning an extracellular region of a receptor polypeptide having the amino acid sequence of Fig. 4 (SEQ ID NO. 4).

23. The nucleic acid molecule of claim 22 wherein the extracellular region is the N-terminal extracellular region.

24. The nucleic acid molecule of claim 20 wherein the PF4AR polypeptide comprises the amino acid sequence of Fig. 4 (SEQ ID NO. 4).

25. A DNA molecule comprising a stretch of at least about 45 contiguous nucleotides selected from or complementary to the DNA sequence of Fig. 4 (SEQ ID NO. 3).

26. The DNA molecule of claim 25 comprising the DNA sequence of Fig. 4 (SEQ ID NO. 3) or its complement.

27. The nucleic acid molecule of claim 20 operably linked to a promoter.

28. An expression vector comprising the nucleic acid molecule of claim 20 operably linked to control sequences recognized by a host cell transformed with the vector.

29. A host cell transformed with the vector of claim 28.

30. A method of using the nucleic acid molecule of claim 20 for the expression of the PF4AR polypeptide encoded by the nucleic acid molecule, comprising culturing a host cell transformed with a vector comprising the nucleic acid molecule operably linked to control sequences recognized by the host cell under conditions that allow expression of the polypeptide.

31. The method of claim 30 further comprising recovering the polypeptide from the host cell.

32. A method for determining the presence or absence of a platelet factor 4 superfamily receptor (PF4AR) nucleic acid in a sample, comprising the steps of:

(a) selecting a probe comprising at least 20 contiguous nucleotides selected from the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3) or at least 20 contiguous nucleotides complementary to the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3),

(b) hybridizing the probe to any PF4AR nucleic acid present in the sample to form a probe/PF4AR nucleic acid complex,

(c) detecting the presence or absence of the probe/PF4AR nucleic acid complex in the sample, and

(d) determining the presence or absence of PF4AR nucleic acid in the sample based on the result of step (c).

33. A method of amplifying a platelet factor 4 superfamily receptor (PF4AR) single stranded nucleic acid in a sample, comprising the steps of:

- (a) selecting an oligonucleotide primer having a 3' terminus consisting of at least 20 contiguous nucleotides selected from the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3) or at least 20 contiguous nucleotides complementary to the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3),
- (b) hybridizing the oligonucleotide primer to the single stranded nucleic acid in the sample, and
- (c) performing a nucleic acid polymerase reaction wherein the hybridized oligonucleotide primer primes the synthesis of a second strand complementary to the single stranded nucleic acid to form an amplified nucleic acid.--

REMARKS

Claims 1-19 are pending in this application. Claims 1-19 are now canceled and new claims 20-33 are added. Thus, claims 20-33 are active in the case.

Amendments

The specification is amended to recite the file history of the present application.

The Sequence Listing in the specification is amended to provide separate SEQ ID numbers for the paired amino acid and nucleotide sequences given a common number in the original Sequence Listing. The specification is further amended to refer to the correct SEQ ID numbers.

Claims 1-19 are canceled and new claims 20-33 are added in order to introduce claims relating to the subject matter of non-elected Claim Group III set forth in the Restriction Requirement and Office Action mailed March 19, 1997 in parent application U.S. Serial No. 08/701,265. Claim Group III encompassed claims 27-40 of parent application U.S. Serial No. 08/701,265, drawn to nucleic acid molecules encoding PF4AR polypeptides, vectors and host cells containing such nucleic acid molecules, and methods of using the same.

Claim 20 is drawn to "[a]n isolated nucleic acid molecule encoding a platelet factor 4

superfamily receptor (PF4AR) polypeptide comprising a stretch of at least 10 contiguous amino acid residues selected from an extracellular region of a receptor polypeptide having the amino acid sequence of Fig. 4 (SEQ ID NO. 4)", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 21, lines 8-20, and page 21, line 31 to page 22, line 12 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 7 of parent application Ser. No. 07/810,782 filed December 19, 1991, now abandoned, the entire disclosure of which is incorporated by reference on page 1, lines 12-15 and page 61, lines 3-4 of the present application.

Claim 21 is drawn to the "nucleic acid molecule of claim 20 wherein the extracellular region is the N-terminal extracellular region", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 21, lines 8-20, and page 21, line 31 to page 22, line 12 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 7 of parent application Ser. No. 07/810,782.

Claim 22 is drawn to the "nucleic acid molecule of claim 20 wherein the PF4AR polypeptide comprises an amino acid sequence spanning an extracellular region of a receptor polypeptide having the amino acid sequence of Fig. 4 (SEQ ID NO. 4)", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 21, lines 8-20, and page 21, line 31 to page 22, line 12 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 7 of parent application Ser. No. 07/810,782.

Claim 23 is drawn to the "nucleic acid molecule of claim 22 wherein the extracellular region is the N-terminal extracellular region", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 21, lines 8-20, and page 21, line 31 to page 22, line 12 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 7 of parent application Ser. No. 07/810,782.

Claim 24 is drawn to the "nucleic acid molecule of claim 20 wherein the PF4AR polypeptide comprises the amino acid sequence of Fig. 4 (SEQ ID NO. 4)", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 13, lines 14-25, and page 21, line 31 to page 22, line 12 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 7 of parent application Ser. No.

07/810,782.

Claim 25 is drawn to a "DNA molecule comprising a stretch of at least about 45 contiguous nucleotides selected from or complementary to the DNA sequence of Fig. 4 (SEQ ID NO. 3)", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, and page 13, lines 14-25 and in Example 2 of the specification and in Fig. 4, and in original claims 6-8 of parent application Ser. No. 07/810,782.

Claim 26 is drawn to the "DNA molecule of claim 25 comprising the DNA sequence of Fig. 4 (SEQ ID NO. 3) or its complement", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, and page 13, lines 14-25 and in Example 2 of the specification and in Fig. 4, and in original claim 7 of parent application Ser. No. 07/810,782.

Claim 27 is drawn to the "nucleic acid molecule of claim 20 operably linked to a promoter", as supported, at least, on page 4, line 30 to page 5, line 2, page 5, lines 3-6, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 14, lines 11-32, page 21, lines 8-20, page 21, line 31 to page 22, line 12, and page 32, line 20 to page 35, line 16 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 9 of parent application Ser. No. 07/810,782.

Claim 28 is drawn to an "expression vector comprising the nucleic acid molecule of claim 20 operably linked to control sequences recognized by a host cell transformed with the vector", as supported, at least, on page 4, line 30 to page 5, line 2, page 5, lines 3-6, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 14, lines 11-32, page 21, lines 8-20, page 21, line 31 to page 22, line 12, and page 28, line 23 to page 37, line 19 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 10 of parent application Ser. No. 07/810,782.

Claim 29 is drawn to a "host cell transformed with the vector of claim 28", as supported, at least, on page 4, line 30 to page 5, line 2, page 5, lines 3-6, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 14, lines 11-32, page 21, lines 8-20, page 21, line 31 to page 22, line 12, page 28, line 23 to page 37, line 19, and page 37, line 20 to page 41, line 4 and in Example 2 of the specification and in Fig. 4, and in original claims 6, 10 and 11 of parent application Ser. No. 07/810,782.

Claim 30 and 31 are drawn to a "method of using the nucleic acid molecule of claim

20 for the expression of the PF4AR polypeptide encoded by the nucleic acid molecule, comprising culturing a host cell transformed with a vector comprising the nucleic acid molecule operably linked to control sequences recognized by the host cell under conditions that allow expression of the polypeptide" and to "recovering the polypeptide from the host cell", respectively, as supported, at least, on page 4, line 30 to page 5, line 2, page 5, lines 3-10, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 14, lines 11-32, page 21, lines 8-20, page 21, line 31 to page 22, line 12, page 28, line 23 to page 37, line 19, page 37, line 20 to page 41, line 4, and page 41, line 5 to page 44, line 23 and in Example 2 of the specification and in Fig. 4, and in original claims 12 and 13 of parent application Ser. No. 07/810,782.

Claim 32 is drawn to a "method for determining the presence or absence of a platelet factor 4 superfamily receptor (PF4AR) nucleic acid in a sample, comprising the steps of: (a) selecting a probe comprising at least 20 contiguous nucleotides selected from the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3) or at least 20 contiguous nucleotides complementary to the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3), (b) hybridizing the probe to any PF4AR nucleic acid present in the sample to form a probe/PF4AR nucleic acid complex, (c) detecting the presence or absence of the probe/PF4AR nucleic acid complex in the sample, and (d) determining the presence or absence of PF4AR nucleic acid in the sample based on the result of step (c)", as supported, at least, on page 5, lines 10-11, page 13, lines 14-25, page 16, line 20 to page 17, line 21, and page 55, lines 22-27 and in Example 2 of the specification and in Fig. 4, and in original claim 14 of parent application Ser. No. 07/810,782.

Claim 33 is drawn to a "method of amplifying a platelet factor 4 superfamily receptor (PF4AR) single stranded nucleic acid in a sample, comprising the steps of: (a) selecting an oligonucleotide primer having a 3' terminus consisting of at least 20 contiguous nucleotides selected from the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3) or at least 20 contiguous nucleotides complementary to the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3), (b) hybridizing the oligonucleotide primer to the single stranded nucleic acid in the sample, and (c) performing a nucleic acid polymerase reaction wherein the hybridized oligonucleotide primer primes the synthesis of a second strand complementary to the single stranded

nucleic acid to form an amplified nucleic acid", as supported, at least, page 13, lines 14-25, page 16, line 20 to page 17, line 21, and page 18, lines 12-20 and in Example 2 of the specification and in Fig. 4, and in original claim 15 of parent application Ser. No. 07/810,782.

No new matter is believed to be added hereby.

Applicants respectfully request entry of the above amendments and early examination of the application.

Respectfully submitted,
GENENTECH, INC.


Date: June 24, 1998

By: 

Richard B. Love
Reg. No. 34, 659

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5530
Fax: (650) 952-9881

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Rule 53(b) Divisional Application of James Lee et al. Serial No.: 08/701,265 Filed: 22 August 1996 For: ANTIBODIES TO HUMAN PF4A RECEPTOR AND COMPOSITIONS THEREOF	Group Art Unit: 1644 Examiner: P. Nolan <div style="text-align: center;"><small>CERTIFICATE OF MAILING</small> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on  June 24, 1998 Yvonne E. Carter</div>
--	---

CERTIFICATE RE: SEQUENCE LISTING

RESPONSE UNDER 37 CFR § 1.821(f) and (g)

BOX SEQUENCE


Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the content of the paper and computer readable copies are the same. I further state that this submission includes no new matter.

Respectfully submitted,
GENENTECH, INC.

Date: June 24, 1998

By: 
Richard B. Love
Reg. No. 34,659

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5530
Fax: (650) 952-9881

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Lee, James
Wood, William I.

(ii) TITLE OF INVENTION: PF4A Receptors

(iii) NUMBER OF SEQUENCES: 6

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genentech, Inc.
(B) STREET: 1 DNA Way
(C) CITY: South San Francisco
(D) STATE: California
(E) COUNTRY: USA
(F) ZIP: 94080

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: WinPatin (Genentech)

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 24-June-1998
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/701265
(B) FILING DATE: 22-AUG-1996

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/664228
(B) FILING DATE: 06-JUN-1996

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/076093
(B) FILING DATE: 11-JUN-1993

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/810782
(B) FILING DATE: 19-DEC-1991

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Love, Richard B.
(B) REGISTRATION NUMBER: 34,659
(C) REFERENCE/DOCKET NUMBER: P0706P2C2

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 415/225-5530
(B) TELEFAX: 415/952-9881
(C) TELEX: 910/371-7168

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1933 base pairs
 (B) TYPE: Nucleic Acid
 (C) STRANDEDNESS: Single
 (D) TOPOLOGY: Linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

10 CCTGGCCGGT GCTTCAGTTA GATCAAACCA TTGCTGAAAC TGAAGAGGAC 50
 100 ATGTCAAATA TTACAGATCC ACAGATGTGG GATTTTGATG ATCTAAATTT 100
 150 CACTGGCATG CCACCTGCAG ATGAAGATTA CAGCCCCTGT ATGCTAGAAA 150
 15 CTGAGACACT CAACAAGTAT GTTGTGATCA TCGCCTATGC CCTAGTGTTT 200
 200 CTGCTGAGCC TGCTGGGAAA CTCCCTGGTG ATGCTGGTCA TCTTATACAG 250
 250 CAGGGTCGGC CGCTCCGTCA CTGATGTCTA CCTGCTGAAC CTGGCCTTGG 300
 300 CCGACCTACT CTTTGCCCTG ACCTTGCCCA TCTGGGCCGC CTCCAAGGTG 350
 350 AATGGCTGGA TTTTGGCAC ATTCTGTGC AAGGTGGTCT CACTCCTGAA 400
 400 GGAAGTCAAC TTCTACAGTG GCATCCTGCT GTTGGCCTGC ATCAGTGTGG 450
 450 ACCGTTACCT GGCCATTGTC CATGCCACAC GCACACTGAC CCAGAAGCGT 500
 500 CACTTGGTCA AGTTTGTGTTG TCTTGGCTGC TGGGGACTGT CTATGAATCT 550
 550 GTCCCTGCCC TTCTTCCTTT TCCGCCAGGC TTACCATCCA AACAAATCCA 600
 600 GTCCAGTTTG CTATGAGGTC CTGGGAAATG ACACAGCAAA ATGGCGGATG 650
 650 GTGTTGCGGA TCCTGCCTCA CACCTTTGGC TTCATCGTGC CGCTGTTTGT 700
 700 CATGCTGTTT TGCTATGGAT TCACCCTGCG TACACTGTTT AAGGCCACCA 750
 750 TGGGGCAGAA GCACCGAGCC ATGAGGGTCA TCTTTGCTGT CGTCCTCATC 800
 800 TTCCTGCTTT GCTGGCTGCC CTACAACCTG GTCCTGCTGG CAGACACCCT 850
 850 CATGAGGACC CAGGTGATCC AGGAGACCTG TGAGCGCCGC AACAAATCG 900
 900 GCCGGGCCCT GGATGCCACT GAGATTCTGG GATTTCTCCA TAGCTGCCTC 950
 950 AACCCCATCA TCTACGCCTT CATCGGCCAA AATTTTCGCC ATGGATTCCT 1000
 1000 CAAGATCCTG GCTATGCATG GCCTGGTCAG CAAGGAGTTC TTGGCACGTC 1050
 1050 ATCGTGTTAC CTCCTACACT TCTTCGTCTG TCAATGTCTC TTCCAACCTC 1100
 1100 TGAAAACCAT CGATGAAGGA ATATCTCTTC TCAGAAGGAA AGAATAACCA 1150
 1150 ACACCCTGAG GTTGTGTGTG GAAGGTGATC TGGCTCTGGA CAGGCACTAT 1200
 1200 CTGGGTTTTG GGGGGACGCT ATAGGATGTG GGGAAAGTTAG GAACTGGTGT 1250
 1250 CTTCAGGGGC CACACCAACC TTCTGAGGAG CTGTTGAGGT ACCTCCAAGG 1300

5

10

15

20

25

30

35

40

45

50

55

ACCGGCCTTT GCACCTCCAT GGAAACGAAG CACCATCATT CCCGTTGAAC 1350
 GTCACATCTT TAACCCACTA ACTGGCTAAT TAGCATGGCC ACATCTGAGC 1400
 CCCGAATCTG ACATTAGATG AGAGAACAGG GCTGAAGCTG TGTCCTCATG 1450
 AGGGCTGGAT GCTCTCGTTG ACCCTCACAG GAGCATCTCC TCAACTCTGA 1500
 GTGTTAAGCG TTGAGCCACC AAGCTGGTGG CTCTGTGTGC TCTGATCCGA 1550
 GCTCAGGGGG GTGGTTTTTC CATCTCAGGT GTGTTGCAGT GTCTGCTGGA 1600
 GACATTGAGG CAGGCACTGC CAAAACATCA ACCTGCCAGC TGGCCTTGTG 1650
 AGGAGCTGGA AACACATGTT CCCCTTGGGG GTGGTGGATG AACAAAGAGA 1700
 AAGAGGGTTT GGAAGCCAGA TCTATGCCAC AAGAACCCCC TTTACCCCCA 1750
 TGACCAACAT CGCAGACACA TGTGCTGGCC ACCTGCTGAG CCCCAGTGG 1800
 AACGAGACAA GCAGCCCTTA GCCCTTCCCC TCTGCAGCTT CCAGGCTGGC 1850
 GTGCAGCATC AGCATCCCTA GAAAGCCATG TGCAGCCACC AGTCCATTGG 1900
 GCAGGCAGAT GTTCCTAATA AAGCTTCTGT TCC 1933

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 350 amino acids
- (B) TYPE: Amino Acid
- (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Ser	Asn	Ile	Thr	Asp	Pro	Gln	Met	Trp	Asp	Phe	Asp	Asp	Leu	1	5	10	15
Asn	Phe	Thr	Gly	Met	Pro	Pro	Ala	Asp	Glu	Asp	Tyr	Ser	Pro	Cys	20	25	30	
Met	Leu	Glu	Thr	Glu	Thr	Leu	Asn	Lys	Tyr	Val	Val	Ile	Ile	Ala	35	40	45	
Tyr	Ala	Leu	Val	Phe	Leu	Leu	Ser	Leu	Leu	Gly	Asn	Ser	Leu	Val	50	55	60	
Met	Leu	Val	Ile	Leu	Tyr	Ser	Arg	Val	Gly	Arg	Ser	Val	Thr	Asp	65	70	75	
Val	Tyr	Leu	Leu	Asn	Leu	Ala	Leu	Ala	Asp	Leu	Leu	Phe	Ala	Leu	80	85	90	
Thr	Leu	Pro	Ile	Trp	Ala	Ala	Ser	Lys	Val	Asn	Gly	Trp	Ile	Phe	95	100	105	
Gly	Thr	Phe	Leu	Cys	Lys	Val	Val	Ser	Leu	Leu	Lys	Glu	Val	Asn	110	115	120	

	Phe Tyr Ser Gly	Ile Leu Leu Leu Ala Cys	Ile Ser Val Asp Arg
		125	130 135
5	Tyr Leu Ala Ile	Val His Ala Thr Arg Thr	Leu Thr Gln Lys Arg
		140	145 150
	His Leu Val Lys	Phe Val Cys Leu Gly Cys	Trp Gly Leu Ser Met
		155	160 165
10	Asn Leu Ser Leu	Pro Phe Phe Leu Phe Arg	Gln Ala Tyr His Pro
		170	175 180
	Asn Asn Ser Ser	Pro Val Cys Tyr Glu Val	Leu Gly Asn Asp Thr
		185	190 195
15	Ala Lys Trp Arg	Met Val Leu Arg Ile Leu	Pro His Thr Phe Gly
		200	205 210
	Phe Ile Val Pro	Leu Phe Val Met Leu Phe	Cys Tyr Gly Phe Thr
		215	220 225
20	Leu Arg Thr Leu	Phe Lys Ala His Met Gly	Gln Lys His Arg Ala
		230	235 240
25	Met Arg Val Ile	Phe Ala Val Val Leu Ile	Phe Leu Leu Cys Trp
		245	250 255
	Leu Pro Tyr Asn	Leu Val Leu Leu Ala Asp	Thr Leu Met Arg Thr
		260	265 270
30	Gln Val Ile Gln	Glu Thr Cys Glu Arg Arg	Asn Asn Ile Gly Arg
		275	280 285
	Ala Leu Asp Ala	Thr Glu Ile Leu Gly Phe	Leu His Ser Cys Leu
		290	295 300
35	Asn Pro Ile Ile	Tyr Ala Phe Ile Gly Gln	Asn Phe Arg His Gly
		305	310 315
40	Phe Leu Lys Ile	Leu Ala Met His Gly Leu	Val Ser Lys Glu Phe
		320	325 330
	Leu Ala Arg His	Arg Val Thr Ser Tyr Thr	Ser Ser Ser Val Asn
		335	340 345
45	Val Ser Ser Asn	Leu	
		350	

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1737 base pairs
 - (B) TYPE: Nucleic Acid
 - (C) STRANDEDNESS: Single
 - (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GAATTCCAGT GTGCTGGCGG CGCGGCGCAA AGTGACGCCG AGGGCCTGAG 50
 TGCTCCAGTA GCCACCGCAT CTGGAGAACC AGCGGTTACC ATGGAGGGGA 100
 TCAGTATATA CACTTCAGAT AACTACACCG AGGAAATGGG CTCAGGGGAC 150
 TATGACTCCA TGAAGGAACC CTGTTTCCGT GAAGAAAATG CTAATTTCAA 200
 TAAAATCTTC CTGCCCACCA TCTACTCCAT CATCTTCTTA ACTGGCATTG 250
 TGGGCAATGG ATTGGTCATC CTGGTCATGG GTTACCAGAA GAAACTGAGA 300
 AGCATGACGG ACAAGTACAG GCTGCACCTG TCAGTGGCCG ACCTCCTCTT 350
 TGTCATCACG CTTCCCTTCT GGGCAGTTGA TGCCGTGGCA AACTGGTACT 400
 TTGGGAACCTT CCTATGCAAG GCAGTCCATG TCATCTACAC AGTCAACCTC 450
 TACAGCAGTG TCCTCATCCT GGCCTTCATC AGTCTGGACC GCTACCTGGC 500
 CATCGTCCAC GCCACCAACA GTCAGAGGCC AAGGAAGCTG TTGGCTGAAA 550
 AGGTGGTCTA TGTTGGCGTC TGGATCCCTG CCCTCCTGCT GACTATTCCC 600
 GACTTCATCT TTGCCAACGT CAGTGAGGCA GATGACAGAT ATATCTGTGA 650
 CCGCTTCTAC CCCAATGACT TGTGGGTGGT TGTGTTCCAG TTTCAGCACA 700
 TCATGGTTGG CCTTATCCTG CCTGGTATTG TCATCCTGTC CTGCTATTGC 750
 ATTATCATCT CCAAGCTGTC ACACTCCAAG GGCCACCAGA AGCGCAAGGC 800
 CCTCAAGACC ACAGTCATCC TCATCCTGGC TTTCTTCGCC TGTTGGCTGC 850
 CTTACTACAT TGGGATCAGC ATCGACTCCT TCATCCTCCT GGAAATCATC 900
 AAGCAAGGGT GTGAGTTTGA GAACACTGTG CACAAGTGA TTTCCATCAC 950
 CGAGGCCCTA GCTTCTTCC ACTGTTGTCT GAACCCCATC CTCTATGCTT 1000
 TCCTTGAGC CAAATTTAAA ACCTCTGCCC AGCACGCACT CACCTCTGTG 1050
 AGCAGAGGGT CCAGCCTCAA GATCCTCTCC AAAGGAAAGC GAGGTGGACA 1100
 TTCATCTGTT TCCACTGAGT CTGAGTCTTC AAGTTTTAC TCCAGCTAAC 1150
 ACAGATGTAA AAGACTTTTT TTTATACGAT AAATAACTTT TTTTAAAGTT 1200
 ACACATTTTT CAGATATAAA AGACTGACCA ATATTGTACA GTTTTTATTG 1250
 CTTGTTGGAT TTTTGTCTTG TGTTTCTTGA GTTTTTGTGA AGTTTAATTG 1300
 ACTTATTTAT ATAAATTTTT TTTGTTTCAT ATTGATGTGT GTCTAGGCAG 1350
 GACCTGTGGC CAAGTTCTTA GTTGCTGTAT GTCTCGTGGT AGGACTGTAG 1400
 AAAAGGGAAC TGAACATTCC AGAGCGTGTA GTGAATCACG TAAAGCTAGA 1450
 AATGATCCCC AGCTGTTTAT GCATAGATAA TCTCTCCATT CCCGTGGAAC 1500

GTTTTTCCTG TTCTTAAGAC GTGATTTTGC TGTAGAAGAT GGCACCTTATA 1550
 ACCAAAGCCC AAAGTGGTAT AGAAATGCTG GTTTTTCAGT TTTCAGGAGT 1600
 GGGTTGATTT CAGCACCTAC AGTGTACAGT CTTGTATTAA GTTGTTAATA 1650
 AAAGTACATG TTAAACTTAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1700
 AAAAAAAAAA AAAGCGGCCG CCAGCACACT GGAATTC 1737

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 352 amino acids

(B) TYPE: Amino Acid

(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Glu	Gly	Ile	Ser	Ile	Tyr	Thr	Ser	Asp	Asn	Tyr	Thr	Glu	Glu	1	5	10	15
Met	Gly	Ser	Gly	Asp	Tyr	Asp	Ser	Met	Lys	Glu	Pro	Cys	Phe	Arg	20	25	30	
Glu	Glu	Asn	Ala	Asn	Phe	Asn	Lys	Ile	Phe	Leu	Pro	Thr	Ile	Tyr	35	40	45	
Ser	Ile	Ile	Phe	Leu	Thr	Gly	Ile	Val	Gly	Asn	Gly	Leu	Val	Ile	50	55	60	
Leu	Val	Met	Gly	Tyr	Gln	Lys	Lys	Leu	Arg	Ser	Met	Thr	Asp	Lys	65	70	75	
Tyr	Arg	Leu	His	Leu	Ser	Val	Ala	Asp	Leu	Leu	Phe	Val	Ile	Thr	80	85	90	
Leu	Pro	Phe	Trp	Ala	Val	Asp	Ala	Val	Ala	Asn	Trp	Tyr	Phe	Gly	95	100	105	
Asn	Phe	Leu	Cys	Lys	Ala	Val	His	Val	Ile	Tyr	Thr	Val	Asn	Leu	110	115	120	
Tyr	Ser	Ser	Val	Leu	Ile	Leu	Ala	Phe	Ile	Ser	Leu	Asp	Arg	Tyr	125	130	135	
Leu	Ala	Ile	Val	His	Ala	Thr	Asn	Ser	Gln	Arg	Pro	Arg	Lys	Leu	140	145	150	
Leu	Ala	Glu	Lys	Val	Val	Tyr	Val	Gly	Val	Trp	Ile	Pro	Ala	Leu	155	160	165	
Leu	Leu	Thr	Ile	Pro	Asp	Phe	Ile	Phe	Ala	Asn	Val	Ser	Glu	Ala	170	175	180	
Asp	Asp	Arg	Tyr	Ile	Cys	Asp	Arg	Phe	Tyr	Pro	Asn	Asp	Leu	Trp	185	190	195	
Val	Val	Val	Phe	Gln	Phe	Gln	His	Ile	Met	Val	Gly	Leu	Ile	Leu				

		200		205		210
	Pro Gly Ile Val	Ile Leu Ser Cys Tyr	Cys Ile Ile Ile Ser	Lys		
		215		220		225
5	Leu Ser His Ser	Lys Gly His Gln Lys	Arg Lys Ala Leu Lys	Thr		
		230		235		240
	Thr Val Ile Leu	Ile Leu Ala Phe Phe	Ala Cys Trp Leu Pro	Tyr		
		245		250		255
10	Tyr Ile Gly Ile	Ser Ile Asp Ser Phe	Ile Leu Leu Glu Ile	Ile		
		260		265		270
	Lys Gln Gly Cys	Glu Phe Glu Asn Thr	Val His Lys Trp Ile	Ser		
15		275		280		285
	Ile Thr Glu Ala	Leu Ala Phe Phe His	Cys Cys Leu Asn Pro	Ile		
		290		295		300
20	Leu Tyr Ala Phe	Leu Gly Ala Lys Phe	Lys Thr Ser Ala Gln	His		
		305		310		315
	Ala Leu Thr Ser	Val Ser Arg Gly Ser	Ser Leu Lys Ile Leu	Ser		
		320		325		330
25	Lys Gly Lys Arg	Gly Gly His Ser Ser	Val Ser Thr Glu Ser	Glu		
		335		340		345
	Ser Ser Ser Phe	His Ser Ser				
30		350		352		

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1679 base pairs
 - (B) TYPE: Nucleic Acid
 - (C) STRANDEDNESS: Single
 - (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

	GAATTCCAGT GTGCTGGCGG CCGCCCAGTG TGCTGGCGGC GGCAGTTGAG	50
45	GGAAAGGACA GAGGTTATGA GTGCCTGCAA GAGTGGCAGC CTGGAGTAGA	100
	GAAAACACTA AAGGTGGAGT CAAAAGACCT GAGTTCAAGT CCCAGCTCTG	150
	CCACTGGTTA GCTGTGGGAT CTCGGAAAAG ACCCAGTGAA AAAAAAAAAA	200
50	AAAGTGATGA GTTGTGAGGC AGGTCGCGGC CCTACTGCCT CAGGAGACGA	250
	TGCGCAGCTC ATTTGCTTAA ATTTGCAGCT GACGGCTGCC ACCTCTCTAG	300
55	AGGCACCTGG CGGGGAGCCT CTCAACATAA GACAGTGACC AGTCTGGTGA	350
	CTCACAGCCG GCACAGCCAT GAACTACCCG CTAACGCTGG AAATGGACCT	400

CGAGAACCTG GAGGACCTGT TCTGGGAAGT GGACAGATTG GACAACTATA 450
ACGACACCTC CCTGGTGGAA AATCATCTCT GCCCTGCCAC AGAGGGGGCCC 500
CTCATGGCCT CCTTCAAGGC CGTGTTCGTG CCCGTGGCCT ACAGCCTCAT 550
CTTCCTCCTG GCGGTGATCG GCAACGTCCT GGTGCTGGTG ATCCTGGAGC 600
GGCACCGGCA GACACGCAGT TCCACGGAGA CCTTCCTGTT CCACCTGGCC 650
GTGGCCGACC TCCTGCTGGT CTTTCATCTTG CCCTTTGCCG TGGCCGAGGG 700
CTCTGTGGGC TGGGTCCTGG GGACCTTCCT CTGCAAAACT GTGATTGCCC 750
TGACAAAAGT CAACTTCTAC TGCAGCAGCC TGCTCCTGGC CTGCATCGCC 800
GTGGACCGCT ACCTGGCCAT TGTCCACGCC GTCCATGCCT ACCGCCACCG 850
CCGCCTCCTC TCCATCCACA TCACCTGTGG GACCATCTGG CTGGTGGGCT 900
TCCTCCTTGC CTTGCCAGAG ATTCTCTTCG CCAAAGTCAG CCAAGGCCAT 950
CACAACAACT CCCTGCCACG TTGCACCTTC TCCCAAGAGA ACCAAGCAGA 1000
AACGCATGCC TGGTTCACCT CCCGATTCCT CTACCATGTG GCGGGATTCC 1050
TGCTGCCCAT GCTGGTGTATG GGCTGGTGCT ACGTGGGGGT AGTGCACAGG 1100
TTGCGCCAGG CCCAGCGGCG CCTCAGCGG CAGAAGGCAG TCAGGGTGGC 1150
CATCCTGGTG ACAAGCATCT TCTTCCTCTG CTGGTCACCC TACCACATCG 1200
TCATCTTCCT GGACACCCTG GCGAGGCTGA AGGCCGTGGA CAATACCTGC 1250
AAGCTGAATG GCTCTCTCCC CGTGGCCATC ACCATGTGTG AGTTCCTGGG 1300
CCTGGCCCAC TGCTGCCTCA ACCCATGCT CTACACTTTC GCCGGCGTGA 1350
AGTTCGCGAG TGACCTGTCT CGGCTCCTGA CGAAGCTGGG CTGTACCGGC 1400
CCTGCCTCCC TGTGCCAGCT CTTCCCTAGC TGGCGCAGGA GCAGTCTCTC 1450
TGAGTCAGAG AATGCCACCT CTCTCACCAC GTTCTAGGTC CCAGTGTCCC 1500
CTTTTATTGC TGCTTTTCCT TGGGGCAGGC AGTGATGCTG GATGCTCCTT 1550
CCAACAGGAG CTGGGATCCT AAGGGCTCAC CGTGGCTAAG AGTGTCTTAG 1600
GAGTATCCTC ATTTGGGGTA GCTAGAGGAA CCAACCCCCA TTTCTAGAAC 1650
ATCCCGCGGC CGCCAGCACA CTGGAATTC 1679

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 372 amino acids
 - (B) TYPE: Amino Acid
 - (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

	Met	Asn	Tyr	Pro	Leu	Thr	Leu	Glu	Met	Asp	Leu	Glu	Asn	Leu	Glu	1	5	10	15
5	Asp	Leu	Phe	Trp	Glu	Leu	Asp	Arg	Leu	Asp	Asn	Tyr	Asn	Asp	Thr	20	25	30	
	Ser	Leu	Val	Glu	Asn	His	Leu	Cys	Pro	Ala	Thr	Glu	Gly	Pro	Leu	35	40	45	
10	Met	Ala	Ser	Phe	Lys	Ala	Val	Phe	Val	Pro	Val	Ala	Tyr	Ser	Leu	50	55	60	
	Ile	Phe	Leu	Leu	Gly	Val	Ile	Gly	Asn	Val	Leu	Val	Leu	Val	Ile	65	70	75	
15	Leu	Glu	Arg	His	Arg	Gln	Thr	Arg	Ser	Ser	Thr	Glu	Thr	Phe	Leu	80	85	90	
20	Phe	His	Leu	Ala	Val	Ala	Asp	Leu	Leu	Leu	Val	Phe	Ile	Leu	Pro	95	100	105	
	Phe	Ala	Val	Ala	Glu	Gly	Ser	Val	Gly	Trp	Val	Leu	Gly	Thr	Phe	110	115	120	
25	Leu	Cys	Lys	Thr	Val	Ile	Ala	Leu	His	Lys	Val	Asn	Phe	Tyr	Cys	125	130	135	
	Ser	Ser	Leu	Leu	Leu	Ala	Cys	Ile	Ala	Val	Asp	Arg	Tyr	Leu	Ala	140	145	150	
30	Ile	Val	His	Ala	Val	His	Ala	Tyr	Arg	His	Arg	Arg	Leu	Leu	Ser	155	160	165	
35	Ile	His	Ile	Thr	Cys	Gly	Thr	Ile	Trp	Leu	Val	Gly	Phe	Leu	Leu	170	175	180	
	Ala	Leu	Pro	Glu	Ile	Leu	Phe	Ala	Lys	Val	Ser	Gln	Gly	His	His	185	190	195	
40	Asn	Asn	Ser	Leu	Pro	Arg	Cys	Thr	Phe	Ser	Gln	Glu	Asn	Gln	Ala	200	205	210	
	Glu	Thr	His	Ala	Trp	Phe	Thr	Ser	Arg	Phe	Leu	Tyr	His	Val	Ala	215	220	225	
45	Gly	Phe	Leu	Leu	Pro	Met	Leu	Val	Met	Gly	Trp	Cys	Tyr	Val	Gly	230	235	240	
50	Val	Val	His	Arg	Leu	Arg	Gln	Ala	Gln	Arg	Arg	Pro	Gln	Arg	Gln	245	250	255	
	Lys	Ala	Val	Arg	Val	Ala	Ile	Leu	Val	Thr	Ser	Ile	Phe	Phe	Leu	260	265	270	
55	Cys	Trp	Ser	Pro	Tyr	His	Ile	Val	Ile	Phe	Leu	Asp	Thr	Leu	Ala	275	280	285	

	Arg	Leu	Lys	Ala	Val	Asp	Asn	Thr	Cys	Lys	Leu	Asn	Gly	Ser	Leu
					290					295					300
	Pro	Val	Ala	Ile	Thr	Met	Cys	Glu	Phe	Leu	Gly	Leu	Ala	His	Cys
					305					310					315
5	Cys	Leu	Asn	Pro	Met	Leu	Tyr	Thr	Phe	Ala	Gly	Val	Lys	Phe	Arg
					320					325					330
	Ser	Asp	Leu	Ser	Arg	Leu	Leu	Thr	Lys	Leu	Gly	Cys	Thr	Gly	Pro
10					335					340					345
	Ala	Ser	Leu	Cys	Gln	Leu	Phe	Pro	Ser	Trp	Arg	Arg	Ser	Ser	Leu
					350					355					360
15	Ser	Glu	Ser	Glu	Asn	Ala	Thr	Ser	Leu	Thr	Thr	Phe			
					365					370		372			

PATENT DUCKET P0706PACADA
EXPRESS MAIL NO. EL14201223705
MAILED: 24 JUNE 1998

ANTIBODIES TO HUMAN PF4A RECEPTORS

This application is a continuation-in-part application of
copending U.S. Serial No. 07/810,782 filed December 19, 1991, which
is a continuation-in-part application of copending U.S. Serial No.
07/677,211 filed 29 March 1991.

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to the field of assaying platelet
factor 4 superfamily members (hereafter "PF4A") and the preparation
of agonists and antagonists to the members of this family, in
particular, antibodies to these receptors.

Description of Background and Related Art

While interleukin-8 was initially identified as a
chemoattractant for neutrophils, and was known to bind a receptor
on neutrophils (Samanta et al., J. Exp. Med., 169: 1185-1189
[1989]; Besemer et al., J. Biol. Chem., 264: 17409-17415 [1989];
Grob et al. J. Biol. Chem., 265: 8311-8316 [1990]), it has in
addition a wide range of pro-inflammatory activities including the
stimulation of degranulation and the upregulation of the cell
adhesion molecule MAC-1 and of the complement receptor CR1.
Oppenheim et al., Annu. Rev. Immunol., 9: 617-648 (1991).

IL-8 is secreted by many cell types in response to pro-inflammatory stimuli such as IL-1 β , TNF, and endotoxin and is a member of a family of ten or more pro-inflammatory cytokines with an $M_r \sim 10,000$. Oppenheim et al., *supra*. This larger family of proteins is called the platelet factor 4 superfamily. Wolpe et al., FASEB J., 3: 2565-73 (1989). Some members of the platelet factor 4 superfamily, in general the subset referred to as C-X-C peptides (including IL-8), possess neutrophil agonist activity, e.g. neutrophil activating protein-2 (NAP-2), platelet factor 4 and NAP-3 (melanoma growth-stimulating activity [MGSA]/gro), all of which are encoded by genes on human chromosome 4. Other members of this family, the C-C peptides, encoded by genes on human chromosome 17, are not neutrophil agonists, and include RANTES, macrophage chemotactic and activating factor (MCAF). Hereafter "PF4A" means the PF4 superfamily. Oppenheim et al., *supra*.

The IL-8 receptors are members of the superfamily of seven transmembrane, G-protein linked receptors. Taylor, Biochem. J., 272: 1 (1990). This family of receptors includes several hundred different receptors among which the β -adrenergic receptor (Strader et al., FASEB, 3: 1825 [1989]; Dixon et al., EMBO J., 6: 3269 [1987]), the muscarinic and cholinergic receptors (Kubo et al., Nature, 323: 411 [1986]; Peralta et al., EMBO J., 6: 3923 [1987]), the c5a and fMet-Leu-Phe receptors. Two types of IL-8 receptors have been described: type A (IL8R-A) (Holmes et al., Science, 253: 1278 [1991]) and type B (IL8R-B) (Murphy and Tiffany, Science, 253: 1280 [1991]) receptors. These two receptors share 77% amino acid identity and have 29-34% sequence homology to C5a and fMet-Leu-Phe. Holmes et al., *supra*. IL8R-A has a high affinity (2 nM) for IL-8 only, while IL8R-B has a high affinity (2 nM) for both IL-8 and MGSA. The function and expression level of each receptor on these cells have yet to be determined.

It is an object of this invention to identify receptors for the PF4A superfamily (hereinafter "PF4AR").

It is another object of this invention to obtain DNA encoding or hybridizing to these receptors, and to express the receptors in host cells.

It is an additional object of this invention to provide isolates of PF4AR for diagnostic and therapeutic purposes.

A still further object is to obtain DNA encoding variants of such receptors and to prepare such variants in recombinant cell culture.

A yet further object is to identify and prepare antibodies to receptors for the PF4A superfamily (hereinafter "PF4AR").

It is still another object to provide a method for treating or preventing an inflammatory response in a mammal using an antibody to such receptors.

These and other objects of this invention will be apparent from the specification as a whole.

SUMMARY OF THE INVENTION

These objects are accomplished, in one aspect, by providing an isolated novel PF4AR polypeptide, including polypeptides that are related structurally to the PF4AR. Members of this class of polypeptide are hereafter generically termed PF4AR, and include derivatives and variants thereof.

Either the whole PF4AR molecule or fragments thereof (which also may be synthesized by chemical methods) fused (by recombinant expression or *in vitro* covalent methods) to an immunogenic polypeptide are used to immunize an animal to raise antibodies against a PF4AR epitope. Anti-PF4AR antibodies are recovered from the serum of immunized animals. Alternatively, monoclonal antibodies are prepared from cells of the immunized animal in conventional fashion.

Thus, in a further aspect, the invention provides an antibody that is capable of binding a PF4AR polypeptide, preferably one that does not cross-react with a receptor capable of binding another PF4

superfamily member. More preferably, the antibody is capable of binding an IL-8 receptor, most preferably an IL-8 type A receptor. Also, the preferred antibody has the isotype IgG1 and/or neutralizes the *in vitro* activity of a PF4AR polypeptide, preferably of an IL-8 type A receptor.

Specific preferred antibodies herein are the monoclonal antibodies designated 2A4, having ATCC Deposit No. HB 11377, and 9H1, having ATCC Deposit No. HB 11376.

Anti-PF4AR antibodies are useful particularly in the diagnosis (*in vitro* or *in vivo*) or (when immobilized on an insoluble matrix) the purification of the PF4AR. The antibodies are also useful in treatment of an inflammatory response in patients. Thus, in another aspect, the invention provides a composition comprising the antibody and a pharmaceutically acceptable carrier, as well as a method for treating an inflammatory disorder which method comprises administering to a mammal in need of such treatment an effective amount of this composition.

Substitutional, deletional, or insertional variants of the PF4AR are prepared by *in vitro* or recombinant methods and screened for immuno-crossreactivity with the PF4AR and for PF4AR antagonist or agonist activity.

The PF4AR also is derivatized *in vitro* to prepare immobilized PF4AR and labeled PF4AR, particularly for purposes of diagnosis of PF4AR or its antibodies, or for affinity purification of PF4AR antibodies.

The PF4AR, its derivatives, or its antibodies are formulated into physiologically acceptable vehicles, especially for therapeutic use. Such vehicles include sustained-release formulations of the PF4AR.

In still other aspects, the invention provides an isolated nucleic acid molecule encoding the PF4AR, labeled or unlabeled, and a nucleic acid sequence that is complementary to, or hybridizes

under suitable conditions to a nucleic acid sequence encoding the PF4AR.

In addition, the invention provides a replicable vector comprising the nucleic acid molecule encoding the PF4AR operably linked to control sequences recognized by a host transformed by the vector; host cells transformed with the vector; and a method of using a nucleic acid molecule encoding the PF4AR to effect the production of PF4AR, comprising expressing the nucleic acid molecule in a culture of the transformed host cells and recovering the PF4AR from the host cell culture. The nucleic acid sequence is also useful in hybridization assays for PF4AR nucleic acid. The recombinant host cells are particularly useful in assaying the appropriate PF4A members.

In further embodiments, the invention provides a method for producing PF4AR comprising inserting into the DNA of a cell containing the nucleic acid encoding the PF4AR a transcription modulatory element in sufficient proximity and orientation to the PF4AR nucleic acid to influence or destroy transcription of DNA encoding a biologically active PF4AR, with an optional further step comprising culturing the cell containing the transcription modulatory element and the PF4AR nucleic acid.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 depicts the high affinity binding of IL-8 to COS cells transfected with clone pRK5B.il8r1.1. a, Competition with unlabelled IL-8 or fMLP. b, Scatchard analysis of the IL-8 competition data; apparent $K_d = 3.6$ nM, average of 820,000 binding sites/cell. Similar competitions with human neutrophils gave $K_d = 1.1$ nM, 31000 binding sites/cell.

Figs. 2a-2c (SEQ ID NO.1) (hereinafter referred to collectively as Fig. 2) depicts the amino acid and nucleotide sequences of the IL-8 receptor cDNA insert from clone pRK5B.il8r1.1. The seven putative transmembrane domains are shown.

There are 4 extracellular segments and 4 intracellular segments, each being separated by one of the transmembrane domains. The extracellular segments are approximately delineated by residues 1-39, 99-111, 134-154, 175-203 and 265-290. The IL-8 receptor contains 3 potential N-linked glycosylation sites in the first extracellular region and 3 more in the third extracellular loop.

Fig. 3a depicts the flow cytometry determination of the intracellular Ca^{++} response of transfected human IL-8 and fMLP receptors to their ligands. Human embryonic kidney 293 cells were transfected by electroporation (Gearing et al. EMBO J., 8: 3667-3676 [1989]) with IL-8 receptor (clone pRK5B.il8r1.1), fMLP receptor (human fMLP receptor cDNA [Boulay et al., Biochem. Biophys. Res. Comm., 168: 1103-1109 (1990)] in the vector pRK5), or vector (pRK5B; EP 307,247) DNA. After two days, the cells were loaded with 2 μM indo-1 acetoxymethyl ester in RPMI medium (Sigma) for 30 min at 37°C. Intracellular Ca^{++} was measured with a Coulter 753 flow cytometer using the ratio of 405 and 525 nm fluorescence. Gryniewicz et al., J. Biol. Chem., 260: 3440-3450 (1985).

Fig. 3b illustrates the percent of cells above 400 nM Ca_i^{++} for the time period after addition of IL-8 (about 15 sec. into each run).

Figs. 4 (SEQ ID NO.2) and 5 (SEQ ID NO.3) depict the DNA and an imputed polypeptide sequences for two additional PF4AR members identified by probing lambda libraries from a human monocyte-like cell line (HL-60) and human PBLs using a large fragment of the IL-8 receptor DNA.

Fig. 6 depicts the structure of the human IL-8 receptor A. 0: glycosylation site. Synthetic peptides covering the extracellular domain of the IL8R-A receptor were made to cover amino acids 2-19, 12-31, 99-110, 176-187, 187-203, 265-277, and 277-291.

Figs. 7A, 7B, 7C, and 7D disclose the binding of monoclonal antibody 2A4 to transfected 293 cells expressing IL8R-A (293-71) (Fig. 7A), transfected 293 cells expressing IL8R-B (293-27) (Fig.

7B), untransfected 293 cells (Fig. 7C), and human neutrophils (Fig. 7D). The solid black line is the Mab 2A4 plus F-G α mIg and the gray line is no Mab plus F-G α mIg (control).

Figs. 8A and 8B show the inhibition of ¹²⁵I-labeled IL-8 binding to human neutrophils (Fig. 8A) and to 293 transfected cells expressing IL8R-A (293-17) (Fig. 8B) by various concentrations of 2A4 (filled circles), 9H1 (open circles), IgG (open triangles), and, for Fig. 8B, no antibody (filled squares). The experiment using human neutrophils was carried out in the presence of various concentrations of MGSA.

Figs. 9A and 9B show the binding of monoclonal antibodies 2A4, 9H1, 4C8, 6E9, and an IgG1 control to various synthetic peptides as determined by ELISA. ELISA plates were coated with 2 μ g/ml of peptides. Experiments were done in triplicates. In Fig. 9A the solid bars are peptide 2-19, the diagonal hatched bars to the right of the solid bar are peptide 12-31, the dark cross-hatching is peptide 99-100, the diagonal hatching to the right of peptide 99-100 is peptide 176-187, the open bars are peptide 187-203, the dotted bars are peptide 264-276, and the horizontal striped bars are peptide 276-290. In Fig. 9B the solid bars are peptide 2-19, the open bars are peptide 1-14, the dotted bars are peptide 1-11, and the diagonal hatching is peptide 1-13 (IL8R-B).

Figure 10 shows the concentrations of IL-8 in sputum from various patients with chronic airway inflammation (cystic fibrosis, bronchiectasis, and chronic bronchitis) and induced sputum for healthy subjects, where the open squares are in-patients and the shaded squares are out-patients.

Detailed Description of the Invention

By expression cloning was isolated a cDNA encoding the human neutrophil IL-8 receptor together with two other homologous receptors. The amino acid sequence shows that the IL-8 receptor is a member of the G-protein coupled receptor family with clear

similarity (29% amino acid identity) to the human neutrophil receptors for the chemoattractants f-Met-Leu-Phe (Boulay et al., supra) and C5a (Gerard and Gerard, Nature, 349: 614-617 [1991]). Although the IL-8 receptor sequence may be the human homologue of what has been identified as the isoform of the rabbit f-Met-Leu-Phe receptor (Thomas et al., J. Biol. Chem., 265: 20061-20064 [1990]), this invention shows that when transfected into mammalian cells, this receptor clone confers high affinity binding to IL-8 and produces a transient Ca^{++} mobilization in response to IL-8 with no binding or response to f-Met-Leu-Phe.

A COS cell expression cloning strategy (Sims et al., Science, 241: 585-589 [1988]); D'Andrea et al., Cell, 57: 277-285 [1989]) was used to isolate clones encoding the IL-8 receptor. A cDNA library constructed from human neutrophil mRNA in the mammalian expression vector pRK5B was transfected into COS-7 cells as pools of 2500 clones, and the cells screened for the binding of ^{125}I -IL-8. One positive pool from the first 58 transfections was partitioned into smaller pools until a pure clone (pRK5B.il8r1.1) was obtained. Figure 1 shows the competition of ^{125}I -IL-8 binding by unlabelled IL-8 to COS cells transfected with the isolated clone. Analysis of this data gives a K_d of 3.6 nM for IL-8 binding which is within the range of 0.8 to 4 nM reported for IL-8 binding to human neutrophils. Samanta et al., supra, Besemer et al., supra, Grob et al., supra. There is no competition of the IL-8 binding by the chemotactic peptide f-Met-Leu-Phe (fMLP).

The DNA sequence of the isolated cDNA clone (Fig. 2) contains a single long open reading frame beginning with a methionine residue that matches the consensus expected for a translation initiation site. Kozak, Nucleic Acid Res., 12: 857-872 (1984). This open reading frame encodes a protein of 350 amino acids (translated M_r 39.5 kD). The amino acid sequence shares several features with the G-protein coupled receptors of the rhodopsin superfamily including seven hydrophobic domains that are presumed

to span the cell membrane and N-linked glycosylation sites near the N-terminus (Dixon et al., Cold Spring Harb. Sym. Quant. Biol., 53: 487-497 [1988]) (see below).

5 The encoded amino acid sequence is the most similar to a recently cloned sequence for the rabbit fMLP receptor. Thomas et al., *supra*. The similarity is sufficiently high (79% amino acid identity overall with multiple stretches of more than 20 contiguous amino acid matches) that these two sequences may well be species homologs of the same receptor. The human fMLP receptor has also
10 been cloned (Boulay et al., *supra*); it has only 26% amino acid identity with the rabbit fMLP receptor (and 29% identity to the human IL-8 receptor presented here). The considerable divergence between the rabbit and human fMLP receptor amino acid sequences has lead to the suggestion in the art (now believed to be possibly erroneous) that these may be two isoforms of the fMLP receptor. Thomas et al., *supra*.

15 Neutrophils respond to the chemoattractants IL-8 and fMLP with a rapid, transient increase in the intracellular free Ca^{++} concentration. Oppenheim et al., *supra*; Korchak et al., J. Biol Chem., 259: 4076-4082 (1984). In order to verify the
20 identification of the clone isolated here as the IL-8 receptor, we have determined the intracellular Ca^{++} response of transfected cells to added IL-8 as well as fMLP. We have used parallel experiments with transfected human fMLP receptor or with the expression vector as controls. Flow cytometer analysis shows a
25 clear transient increase in intracellular Ca^{++} for the transfected IL-8 receptor in response to IL-8. No response is found to fMLP. Conversely, cells transfected with the human fMLP receptor respond to fMLP but not to IL-8. No response to either chemoattractant is
30 found in vector transfected cells. Only a subset of the cells are expected to respond in these experiments as the transfection efficiency is estimated to be 15-25%. Binding experiments (Tennenberg et al., J. Immunol., 141: 3937-3944 [1988]) also failed

to detect any binding of ^3H -fMLP to the expressed IL-8 receptor or ^{125}I -IL-8 to the expressed human fMLP receptor. These experiments clearly demonstrate the specificity of the two receptors for their respective ligands; a result expected based on the lack of binding competition between IL-8 and fMLP for neutrophils. Oppenheim et al., *supra*. These results also demonstrate that the cloned receptors function in second message signaling in response to ligand binding.

Blot hybridization of the cloned IL-8 receptor cDNA to human neutrophil mRNA, shows strong bands of 2.4 and 3.0 kb as well as a fainter band at 3.5 kb. While it is clear from the DNA sequence data presented in Fig. 2 that the mRNA for the receptor has a long 3' untranslated region, additional work will be needed to establish whether the multiple RNA bands are due to multiple polyadenylation sites. No hybridization was detected to mRNA from U266 or Jurkat cell lines, which are of the B cell and T cell lineages. No hybridization was found for mRNA from the monocyte cell line U937 as well, in spite of the reports of low levels of IL-8 binding to these cells. Besemer et al., *supra*; Grob et al., *supra*.

Alignment of the receptor sequences for the three neutrophil chemoattractants IL-8, fMLP (Boulay et al., *supra*), and C5a (Gerard and Gerard, *supra*) shows that they form a subfamily of the G-protein coupled receptors with 29-34 % amino acid identity. This subfamily has a short third intracellular loop as compared with other G-protein coupled receptors such as the β -adrenergic (Dixon et al., *supra*) or muscarinic acetylcholine receptors. Ramachandran, et al., BioEssays, 10: 54-57 (1989). This loop contains determinants at least partially responsible for the binding of G-proteins to the receptors. Dixon et al., *supra*. The intracellular C-terminal region of the IL-8 receptor, while not very similar to that of the fMLP and C5a receptors does preserve a high number of serine and threonine residues that may function as phosphorylation sites. As has been noted for the C5a receptor

(Gerard and Gerard, *supra*), the N-terminal extracellular region for the IL-8 receptor has several acidic residues. These may aid in the binding of IL-8, which is quite basic (pI ~ 9.5).

I. Definitions

In general, the following words or phrases have the indicated definition when used in the description, examples, and claims:

The term "PF4AR" is defined as a polypeptide having a qualitative biological activity in common with the polypeptides of Figs. 2, 4, or 5. Optionally, PF4AR will have at least 30% and ordinarily 75% amino acid sequence identity with any of the polypeptides of Figs. 2, 4 or 5. Optionally, PF4AR excludes the rabbit fMLP receptor (Thomas et al., *supra*), the human fMLP receptor (Boulay et al., *supra*), the human C5a receptor (Gerard and Gerard, *supra*), and/or the receptor described by Murphy and Tiffany, *supra*.

Identity or homology with respect to a PF4AR is defined herein to be the percentage of amino acid residues in the candidate sequence that are identical with the residues in Figs. 2, 4 or 5 after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as representing residue identity. No N- nor C-terminal extensions, deletions nor insertions shall be construed as reducing identity or homology.

PF4AR qualitative biological activity is defined as any one of (1) immunological cross-reactivity with at least one epitope of a polypeptide set forth in Figs. 2, 4, or 5; (2) the ability to specifically bind to a member of the PF4 superfamily; or (3) any effector or functional activity of the Figs. 2, 4 or 5 polypeptides as found in nature, including their ability to bind any ligands other than superfamily members.

Immunologically cross-reactive as used herein means that the candidate polypeptide is capable of competitively inhibiting the binding of a PF4AR to polyclonal antibodies or antisera raised

against a PF4AR. Such antibodies and antisera are prepared in conventional fashion by injecting an animal such as a goat or rabbit, for example, subcutaneously with the known native PF4AR in complete Freund's adjuvant, followed by booster intraperitoneal or subcutaneous injection in incomplete Freund's.

Included within the scope of the PF4AR as that term is used herein are polypeptides having the amino acid sequences described in Figs. 2, 4 or 5, amino acid sequence variants of such amino acid sequences, glycosylation variants of the polypeptides and covalent modifications of the polypeptides. Each of these are described in more detail below.

"Isolated" PF4AR nucleic acid or polypeptide is a PF4AR nucleic acid or polypeptide that is identified and separated from at least one contaminant (nucleic acid or polypeptide respectively) with which it is ordinarily associated in nature, such as from the animal or human source of the PF4AR nucleic acid or polypeptide. In preferred embodiments, the PF4AR will be isolated to pharmaceutically acceptable levels of purity with respect to proteins of its species of origin. In preferred embodiments, PF4AR protein will be purified (1) to greater than 95% by weight of protein as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by an amino acid sequenator commercially available on the filing date hereof, or (3) to homogeneity by conventional nonreducing SDS-PAGE using Coomassie blue or, preferably, silver stain. Isolated PF4AR includes PF4AR in situ within recombinant cells since, in this instance, at least one component of the PF4AR natural environment will not be present. Isolated PF4AR includes PF4AR from one species in a recombinant cell culture of another species since the receptor in such circumstances will be devoid of source polypeptides. Ordinarily, however, isolated receptor will be prepared by at least one purification step.

Isolated PF4AR nucleic acid includes a nucleic acid that is identified and separated from at least one containment nucleic acid with which it is ordinarily associated in the natural source of the receptor nucleic acid. Isolated PF4AR nucleic acid thus is present in other than in the form or setting in which it is found in nature. However, isolated receptor-encoding nucleic acid includes PF4AR nucleic acid in ordinarily receptor-expressing cells where the nucleic acid is in a chromosomal location different from that of natural cells or is otherwise flanked by a different DNA sequence than that found in nature.

The nucleic acid or polypeptide may be labeled for diagnostic and probe purposes, using a label as described and defined further below in the discussion of diagnostic assays.

PF4AR "nucleic acid" is defined as RNA or DNA containing greater than ten bases that encodes a polypeptide sequence within Figs. 2, 4 or 5, is complementary to nucleic acid sequence of Figs. 2, 4 or 5, hybridizes to such nucleic acid and remains stably bound to it under low stringency conditions, or encodes a polypeptide sharing at least 30% sequence identity, preferably at least 75%, and more preferably at least 85%, with the translated amino acid sequence shown in Figs. 2, 4 or 5 or a fragment thereof. Preferably the DNA which hybridizes to the nucleic acid of Figs. 2, 4 or 5 contain at least 20, more preferably 40, and more preferably 60 bases. Most preferably, the hybridizing DNA or RNA contains 45 or even more preferably 90 bases. Such hybridizing or complementary nucleic acid, however, is defined further as being novel and unobvious over any prior art nucleic acid including that which encodes, hybridizes under low stringency conditions, or is complementary to nucleic acid encoding rabbit fMLP receptor (Thomas et al., *supra*), human fMLP receptor or (optionally) the IL-8 receptor of Murphy and Tiffany, *supra*.

"High stringency conditions" are any of those that (1) employ low ionic strength and high temperature for washing, for example,

0.015 M NaCl/0.0015 M sodium citrate/0.1% NaDodSO₄ at 50°C; (2) employ during hybridization 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C; or (3) employ hybridization with 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC and 0.1% SDS. Conditions of low stringency are set forth in Example 2.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.

The starting plasmids herein are commercially available, are publicly available on an unrestricted basis, or can be constructed from such available plasmids in accord with published procedures. In addition, other equivalent plasmids are known in the art and will be apparent to the ordinary artisan. Methods for restriction enzyme digestion, recovery or isolation of DNA, hybridization analysis, and ligation are conventional and by this time well known to the ordinary artisan.

"Recovery" or "isolation" of a given fragment of DNA from a restriction digest means separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. This procedure is known generally. For example, see Lawn et al., Nucleic Acids Res., 9: 6103-6114 (1981), and Goeddel et al., Nucleic Acids Res., 8: 4057 (1980).

As used herein, the term "mammal" refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc. Preferably, the mammal herein is human.

As used herein, the term "treatment" refers to therapy as well as prophylactic (preventative) measures.

As used herein, the term "inflammatory disorders" refers to pathological states resulting in inflammation, typically caused by neutrophil chemotaxis. Examples of such disorders include T cell inflammatory responses such as inflammatory skin diseases including psoriasis; responses associated with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis); adult respiratory distress syndrome; dermatitis; meningitis; encephalitis; uveitis; allergic conditions such as eczema and asthma and other conditions involving infiltration of T cells and chronic inflammatory responses; skin hypersensitivity reactions (including poison ivy

and poison oak); atherosclerosis; leukocyte adhesion deficiency; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), diabetes mellitus, multiple sclerosis, Reynaud's syndrome, autoimmune thyroiditis, experimental autoimmune encephalomyelitis, Sjorgen's syndrome, juvenile onset diabetes, and immune responses associated with delayed hypersensitivity mediated by cytokines and T-lymphocytes typically found in tuberculosis, sarcoidosis, polymyositis, granulomatosis and vasculitis; pernicious anemia; diseases involving leukocyte diapedesis; CNS inflammatory disorder, multiple organ injury syndrome secondary to septicaemia or trauma; autoimmune haemolytic anemia; myethemia gravis; antigen-antibody complex mediated diseases; inflammations of the lung, including pleurisy, alveolitis, vasculitis, pneumonia, chronic bronchitis, bronchiectasis, and cystic fibrosis; etc. The preferred indications are inflammatory bowel disease such as ulcerative colitis or a chronic lung inflammation.

II. Suitable Methods for Practicing the Invention

1. Preparation of Native PF4AR and Variants

A. Isolation of DNA Encoding PF4AR

The DNA encoding of the PF4AR may be obtained from any cDNA library prepared from tissue believed to contain the PF4AR mRNA, generally HL60 or PBL libraries. The PF4AR gene may also be obtained from a genomic library. Libraries are screened with probes designed to identify the gene of interest or the protein encoded by it. The entire cDNA for the IL-8 receptor and two homologous receptors is described. Nucleic acid encoding this family of receptors is readily obtained under low stringency conditions from genomic DNA or neutrophil cDNA libraries using probes having oligonucleotide sequences from the receptor gene sequences of Figs. 2, 4 or 5. These probes usually will contain about 500 or more bases. Since the probes will hybridize perfectly to the three exemplified DNAs, there is no need to use probe pools containing degenerate sequences. Screening with the probes to

identify the Figs. 2, 4 or 5 receptors is more efficient if performed under conditions of high stringency.

Other PF4ARs other than those in Figs. 2, 4 or 5 are believed to exist and to contain regions of homology to the exemplified receptors. Thus probes having the sequences of the DNAs in Figs. 2, 4 or 5 can be used to screen for these receptors as well. The best candidates for probes are long sequences (greater than about 100 bases) that represent sequences that are highly homologous among the three exemplified human receptors. IL-8 cDNA encoding the IL-8 residues 15-34, 78-94, 176-193, 264-282 and 299-312 (and comparable probes from other receptors of the IL-8R family) are useful, particularly in probing for IL-8 receptor DNA. Probes useful for the receptor of Fig. 4 (and isolated proteins characteristic of the Fig. 5 receptor) are represented by sequences comprising residues 1-48, 77-92, 107-137, 156-177, 189-226, 239-257 and 271-315. Homologous probes and residues of the Fig. 4 receptor also are useful, i.e. residues 1-35, 64-78, 94-124, 143-164, 176-197, 219-239 and 251-295. cDNAs comprising cDNA encoding the following regions of the Figs. 2, 4 or 5 polypeptides are useful in probing for other receptors: 92-106, 57-72, 138-154, 314-329 and 57-154.

In general, one first identifies a cell which is capable of specifically binding or which is activated by a given PF4A, typically by *in vitro* bioassays and, optionally, by cell binding analysis using the labelled PF4A. Cells identified by this process (and some are already known for individual PF4As) therefore are expressing a receptor for this PF4A. A cDNA library is prepared from such cells and is screened using the receptor probes by procedures that are conventional per se. In this instance, however, it is preferred to use low stringency conditions (such as those in Example 2) and then analyze the resulting positive clones for homology to the Figs. 2, 4 or 5 receptors. In general, candidate human PF4ARs will exhibit greater than about 30% amino

acid sequence homology to the Figs. 2, 4 or 5 receptors and bear a similar transmembrane loop structure.

Assays are then conducted to confirm that the hybridizing full length genes are the desired PF4AR. The candidate is simply inserted into an expression vector and transformed into a host cell that ordinarily does not bind to the candidate PF4A ligand. Transformants that acquire the ability to bind the ligand thus bear the desired receptor gene. In Example 2, we show that two additional homologous polypeptide sequences representing PR4ARs are identified using IL-8R DNA encoding residues 23-314, although the particular probe is not believed to be critical.

An alternative means to isolate genes encoding additional PF4ARs is to use polymerase chain reaction (PCR) methodology (U.S. Patent 4,683,195; Erlich, ed., PCR Technology, 1989) to amplify the target DNA or RNA, e.g. as described in section 14 of Sambrook et al., *supra*. This method requires the use of oligonucleotide primers that will be expected to hybridize to the PF4AR, and these readily are selected from the receptor cDNAs of Figs. 2, 4 or 5. Strategies for selection of oligonucleotide primers are described above.

cDNA libraries may be screened from various tissues, preferably mammalian PBL, monocyte, placental, fetal, brain, and carcinoma cell lines in order to obtain DNA encoding the receptors of Figs. 2, 4 or 5, or homologous receptors. More preferably, human or rabbit placental, fetal, brain, and carcinoma cell line cDNA libraries are screened with labelled oligonucleotide probes.

Another method for obtaining the gene of interest is to chemically synthesize it using one of the methods described in Engels et al., Agnew. Chem. Int. Ed. Engl., 28: 716-734 (1989), specifically incorporated by reference. These methods include triester, phosphite, phosphoramidite and H-phosphonate methods, typically proceeding by oligonucleotide synthesis on solid supports. These methods may be used if the entire amino acid or

nucleic acid sequence of the gene is known, or the sequence of the nucleic acid complementary to the coding strand is available. If the desired amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue.

B. Amino Acid Sequence Variants of the PF4AR

Amino acid sequence variants of the PF4AR are prepared by introducing appropriate nucleotide changes into the PF4AR DNA, or by *in vitro* synthesis of the desired PF4AR polypeptide. Such variants include, for example, deletions from, or insertions or substitutions of, residues within the amino acid sequence shown for the receptors in Figs. 2, 4 or 5. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics.

The amino acid changes also may alter post-translational processing of the PF4AR, such as changing the number or position of glycosylation sites or by altering its membrane anchoring characteristics. Excluded from the scope of this invention are PF4AR variants or polypeptide sequences that are not statutorily novel and unobvious over the prior art.

In designing amino acid sequence variants of PF4ARs, the location of the mutation site and the nature of the mutation will depend on the PF4AR characteristic(s) to be modified. The sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conservative amino acid choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.

A useful method for identification of certain residues or regions of the PF4AR polypeptide that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" as described

by Cunningham and Wells, Science, 244: 1081-1085 (1989). Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, ala scanning or random mutagenesis may be conducted at the target codon or region and the expressed PF4AR variants are screened for the optimal combination of desired activity.

In general, the regions of the PF4AR molecule preferred for alterations are non-hydrophilic regions or regions that are not highly conserved. Such regions are those in which sequences of 5 or more residues are not substantially conserved in the homologous positions in the rabbit fMLP receptor, the human fMLP receptor, the human C5a receptor and the receptors of Figs. 2, 4 and 5.

PF4AR variants will exhibit at least a biological activity of the parental sequence, for example ligand binding activity or antigenic activity. Antigenically active PF4AR is a polypeptide that binds with an affinity of at least about 10^9 1/mole to an antibody raised against a naturally occurring PF4AR sequence. Ordinarily the polypeptide binds with an affinity of at least about 10^8 1/mole. Most preferably, the antigenically active PF4AR is a polypeptide that binds to an antibody raised against the receptor in its native conformation, "native conformation" generally meaning the receptor as found in nature which has not been denatured by chaotropic agents, heat or other treatment that substantially modifies the three dimensional structure of the receptor (this can

be determined, for example, by migration on nonreducing, nondenaturing sizing gels). Antibody used in determination of antigenic activity is rabbit polyclonal antibody raised by formulating the native non-rabbit receptor in Freund's complete adjuvant, subcutaneously injecting the formulation, and boosting the immune response by intraperitoneal injection of the formulation until the titer of anti-receptor antibody plateaus.

One group of variants are deletion mutants, or fragments of the sequences set forth in Figs. 2, 4, 5 or other PF4AR. In general, the fragments are those which constitute the extracellular regions of the receptors (these receptors are unlike most in that they are believed to contain a plurality of hydrophobic, trans-membrane domains separated by hydrophilic sequences believed to loop into the ectoplasm). Particularly of interest are the N-terminal extracellular region containing acidic amino acid residues. However, any sequence which is capable of raising an antibody that will cross-react with the intact receptor, or which will bind to a member of the PF4 superfamily, is useful. These fragments typically will contain a consecutive sequence of at least about 5 (and ordinarily at least about 10) residues.

Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues, and typically are contiguous. Deletions may be introduced into regions of low homology among the receptors of Figs. 2, 4 and 5 to modify the activity of the receptors. Such deletions will be more likely to modify the biological activity of the receptors more significantly than deletions made elsewhere. The number of consecutive deletions will be selected so as to preserve the tertiary structure of the PF4AR in the affected domain, e.g., beta-pleated sheet or alpha helix.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence

insertions of single or multiple amino acid residues. Intrasequence insertions (i.e., insertions within the PF4AR sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5, most preferably 1 to 3.

Insertional variants of the PF4AR or its extracellular segments include the fusion to the N- or C-terminus of the PF4AR of immunogenic polypeptides, e.g., bacterial polypeptides such as beta-lactamase or an enzyme encoded by the *E. coli* trp locus, or yeast protein, and C-terminal fusions with proteins having a long half-life such as immunoglobulin constant regions (or other immunoglobulin regions), albumin, or ferritin, as described in WO 89/02922 published 6 April 1989.

Another group of variants are amino acid substitution variants. These variants have at least one amino acid residue in the PF4AR molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include sites identified as the active site(s) of the PF4AR, and sites where the amino acids found in the PF4AR from various species are substantially different in terms of side-chain bulk, charge, and/or hydrophobicity.

Other sites of interest are those in which particular residues of the PF4ARs of Figs. 2, 4 and 5 are identical. These positions may be important for the biological activity of the PF4AR. These sites, especially those falling within a sequence of at least three other identically conserved sites, are substituted in a relatively conservative manner. Such conservative substitutions are shown in Table 1 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 1, or as further described below in reference to amino acid classes, are introduced and the products screened.

Table 1

	<u>Original Residue</u>	<u>Exemplary Substitutions</u>	<u>Preferred Substitutions</u>
5	Ala (A)	val; leu; ile	val
	Arg (R)	lys; gln; asn	lys
	Asn (N)	gln; his; lys; arg	gln
	Asp (D)	glu	glu
	Cys (C)	ser	ser
10	Gln (Q)	asn	asn
	Glu (E)	asp	asp
	Gly (G)	pro	pro
	His (H)	asn; gln; lys; arg	arg
	Ile (I)	leu; val; met; ala; phe; norleucine	leu
15	Leu (L)	norleucine; ile; val; met; ala; phe	ile
	Lys (K)	arg; gln; asn	arg
	Met (M)	leu; phe; ile	leu
20	Phe (F)	leu; val; ile; ala	leu
	Pro (P)	gly	gly
	Ser (S)	thr	thr
	Thr (T)	ser	ser
	Trp (W)	tyr	tyr
25	Tyr (Y)	trp; phe; thr; ser	phe
	Val (V)	ile; leu; met; phe; ala; norleucine	leu

Substantial modifications in function or immunological identity of the PF4AR are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are

divided into groups based on common side chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- 5 (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another. Such substituted residues may
10 be introduced into regions of the PF4AR that are homologous with other PF4ARs, or, more preferably, into the non-homologous regions of the molecule.

Any cysteine residues not involved in maintaining the proper conformation of the PF4AR may be substituted, generally with
15 serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking.

DNA encoding amino acid sequence variants of the PF4AR is prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source
20 (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the PF4AR. These techniques may utilize PF4AR nucleic acid (DNA or RNA), or
25 nucleic acid complementary to the PF4AR nucleic acid.

Oligonucleotide-mediated mutagenesis is a preferred method for preparing substitution, deletion, and insertion variants of PF4AR DNA. This technique is well known in the art, for example as described by Adelman et al., DNA, 2: 183 (1983). Briefly, the
30 PF4AR DNA is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the PF4AR. After

hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the PF4AR DNA.

5 Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the
10 single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al., Proc. Natl. Acad. Sci. USA, 75: 5765 (1978).

15 Single-stranded DNA template may also be generated by denaturing double-stranded plasmid (or other) DNA using standard techniques.

20 For alteration of the native DNA sequence (to generate amino acid sequence variants, for example), the oligonucleotide is hybridized to the single-stranded template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of the PF4AR,
25 and the other strand (the original template) encodes the native, unaltered sequence of the PF4AR. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as *E. coli* JM101. The cells are plated onto agarose plates, and screened using the oligonucleotide primer radiolabeled with
30 32-phosphate to identify the bacterial colonies that contain the mutated DNA. The mutated region is then removed and placed in an appropriate vector for protein production, generally an expression

vector of the type typically employed for transformation of an appropriate host.

5 The method described immediately above may be modified such that a homoduplex molecule is created wherein both strands of the plasmid contain the mutation(s). The modifications are as follows: The single-stranded oligonucleotide is annealed to the single-stranded template as described above. A mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP), is combined with a modified thio-deoxyribocytosine called dCTP-(aS) (which can be obtained from Amersham Corporation). This mixture is added to the template-oligonucleotide complex. Upon addition of DNA polymerase to this mixture, a strand of DNA identical to the template except for the mutated bases is generated. In addition, this new strand of DNA will contain dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonuclease digestion. After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with ExoIII nuclease or another appropriate nuclease past the region that contains the site(s) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase. This homoduplex molecule can then be transformed into a suitable host cell such as *E. coli* JM101, as described above.

15 DNA encoding PF4AR mutants at more than one site may be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions. If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to generate a single

oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.

In the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions. The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oligonucleotide encoding the first desired amino acid substitution(s) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitution(s) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA can be used as a template in a third round of mutagenesis, and so on.

PCR mutagenesis is also suitable for making amino acid variants of the PF4AR. While the following discussion refers to DNA, it is understood that the technique also finds application with RNA. The PCR technique generally refers to the following procedure (see Erlich, *supra*, the chapter by R. Higuchi, p. 61-70): When small amounts of template DNA are used as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation; the sequence of the

other primer must be identical to a stretch of sequence of the opposite strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 200 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primers can be easily sequenced. PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.

If the ratio of template to product material is extremely low, the vast majority of product DNA fragments incorporate the desired mutation(s). This product material is used to replace the corresponding region in the plasmid that served as PCR template using standard DNA technology. Mutations at separate positions can be introduced simultaneously by either using a mutant second primer, or performing a second PCR with different mutant primers and ligating the two resulting PCR fragments simultaneously to the vector fragment in a three (or more)-part ligation.

Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells et al., Gene, 34: 315 (1985).

C. Insertion of DNA into a Cloning Vehicle

The cDNA or genomic DNA encoding native or variant PF4AR is inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. Many vectors are available, and selection of the appropriate vector will depend on (1) whether it is to be used for DNA amplification or for DNA expression, (2) the size of the DNA to be inserted into the vector, and (3) the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the host cell for which it is compatible. The vector components generally include,

but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

5 (i) Signal Sequence Component

10 In general, a signal sequence may be a component of the vector, or it may be a part of the PF4AR DNA that is inserted into the vector. The native pro PF4AR DNA is directed to the cell surface in our recombinant cells but it does not contain a conventional signal and no N-terminal polypeptide is cleaved during post-translational processing of the polypeptide during membrane insertion of the PF4AR.

15 (ii) Origin of Replication Component

20 Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 μ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).

25 Most expression vectors are "shuttle" vectors, i.e. they are capable of replication in at least one class of organisms but can be transfected into another organism for expression. For example, a vector is cloned in *E. coli* and then the same vector is transfected into yeast or mammalian cells for expression even

though it is not capable of replicating independently of the host cell chromosome.

DNA may also be amplified by insertion into the host genome. This is readily accomplished using *Bacillus* species as hosts, for example, by including in the vector a DNA sequence that is complementary to a sequence found in *Bacillus* genomic DNA. Transfection of *Bacillus* with this vector results in homologous recombination with the genome and insertion of the PF4AR DNA. However, the recovery of genomic DNA encoding the PF4AR is more complex than that of an exogenously replicated vector because restriction enzyme digestion is required to excise the PF4AR DNA.

(iii) Selection Gene Component

Expression and cloning vectors should contain a selection gene, also termed a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g. ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g. the gene encoding D-alanine racemase for *Bacilli*.

One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene express a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin (Southern et al., J. Molec. Appl. Genet., 1: 327 [1982]), mycophenolic acid (Mulligan et al., Science, 209: 1422 [1980]) or hygromycin (Sugden et al., Mol. Cell. Biol., 5: 410-413 [1985]). The three examples given above employ bacterial genes under eukaryotic control to convey

resistance to the appropriate drug G418 or neomycin (geneticin),
 xgpt (mycophenolic acid), or hygromycin, respectively.

Another example of suitable selectable markers for mammalian
 cells are those that enable the identification of cells competent
 to take up the PF4AR nucleic acid, such as dihydrofolate reductase
 (DHFR) or thymidine kinase. The mammalian cell transformants are
 placed under selection pressure which only the transformants are
 uniquely adapted to survive by virtue of having taken up the
 marker. Selection pressure is imposed by culturing the
 transformants under conditions in which the concentration of
 selection agent in the medium is successively changed, thereby
 leading to amplification of both the selection gene and the DNA
 that encodes the PF4AR. Amplification is the process by which
 genes in greater demand for the production of a protein critical
 for growth are reiterated in tandem within the chromosomes of
 successive generations of recombinant cells. Increased quantities
 of the PF4AR are synthesized from the amplified DNA.

For example, cells transformed with the DHFR selection gene
 are first identified by culturing all of the transformants in a
 culture medium that contains methotrexate (Mtx), a competitive
 antagonist of DHFR. An appropriate host cell when wild-type DHFR
 is employed is the Chinese hamster ovary (CHO) cell line deficient
 in DHFR activity, prepared and propagated as described by Urlaub
 and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216 (1980). The
 transformed cells are then exposed to increased levels of
 methotrexate. This leads to the synthesis of multiple copies of
 the DHFR gene, and, concomitantly, multiple copies of other DNA
 comprising the expression vectors, such as the DNA encoding the
 PF4AR. This amplification technique can be used with any otherwise
 suitable host, e.g., ATCC No. CCL61 CHO-K1, notwithstanding the
 presence of endogenous DHFR if, for example, a mutant DHFR gene
 that is highly resistant to Mtx is employed (EP 117,060).
 Alternatively, host cells (particularly wild-type hosts that

contain endogenous DHFR) transformed or co-transformed with DNA sequences encoding the PF4AR, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3' phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibiotic, e.g., kanamycin, neomycin, or G418. See U.S. Pat. No. 4,965,199.

A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7. Stinchcomb et al., Nature, 282: 39 (1979); Kingsman et al., Gene, 7: 141 (1979); or Tschemper et al., Gene, 10: 157 (1980). The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics, 85: 12 (1977). The presence of the *trp1* lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, *Leu2*-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the *Leu2* gene.

(iv) Promoter Component

Expression vectors usually contain a promoter that is recognized by the host organism and is operably linked to the PF4AR nucleic acid. Promoters are untranslated sequences located upstream (5') to the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of a particular nucleic acid sequence, such as the PF4AR, to which they are operably linked. Such promoters typically fall into two classes, inducible and constitutive. Inducible promoters are promoters that initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, e.g. the presence or absence of a nutrient or a change in temperature. At this time a large number of promoters recognized by a variety of potential host cells are well known. These promoters are operably linked to DNA encoding

the PF4AR by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into the vector. Both the native PF4AR promoter sequence and many heterologous promoters may be used to direct amplification and/or expression of the PF4AR DNA. However, heterologous promoters are preferred, as they generally permit greater transcription and higher yields of expressed PF4AR as compared to the native PF4AR promoter.

Promoters suitable for use with prokaryotic hosts include the β -lactamase and lactose promoter systems (Chang et al., Nature, 275: 615 [1978]; and Goeddel et al., Nature, 281: 544 [1979]), alkaline phosphatase, a tryptophan (trp) promoter system (Goeddel, Nucleic Acids Res., 8: 4057 [1980] and EP 36,776) and hybrid promoters such as the tac promoter (deBoer et al., Proc. Natl. Acad. Sci. USA, 80: 21-25 [1983]). However, other known bacterial promoters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably to ligate them to DNA encoding the PF4AR (Siebenlist et al., Cell, 20: 269 [1980]) using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems also generally will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the PF4AR.

Suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem., 255: 2073 [1980]) or other glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg., 7: 149 [1968]; and Holland, Biochemistry, 17: 4900 [1978]), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth

conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman et al., EP 73,657A. Yeast enhancers also are advantageously used with yeast promoters.

Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CXCAAT region where X may be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding sequence. All of these sequences are suitably inserted into mammalian expression vectors.

PF4AR transcription from vectors in mammalian host cells is controlled by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g. the actin promoter or an immunoglobulin promoter, from heat-shock promoters, and from the promoter normally associated with the PF4AR sequence, provided such promoters are compatible with the host cell systems.

The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication. Fiers et al., Nature, 273: 113 (1978); Mulligan and Berg, Science, 209: 1422-1427 (1980); Pavlakis et al., Proc. Natl. Acad. Sci. USA, 78: 7398-7402 (1981). The immediate early promoter of the human cytomegalovirus

is conveniently obtained as a HindIII E restriction fragment. Greenaway et al., Gene, 18: 355-360 (1982). A system for expressing DNA in mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. 4,419,446. A modification of this system is described in U.S. 4,601,978. See also Gray et al., Nature, 295: 503-508 (1982) on expressing cDNA encoding immune interferon in monkey cells, Reyes et al., Nature, 297: 598-601 (1982) on expression of human β -interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus, Canaani and Berg, Proc. Natl. Acad. Sci. USA, 79: 5166-5170 (1982) on expression of the human interferon β 1 gene in cultured mouse and rabbit cells, and Gorman et al., Proc. Natl. Acad. Sci. USA, 79: 6777-6781 (1982) on expression of bacterial CAT sequences in CV-1 monkey kidney cells, chicken embryo fibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3 cells using the Rous sarcoma virus long terminal repeat as a promoter.

(v) Enhancer Element Component

Transcription of a DNA encoding the PF4AR of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10-300 bp, that act on a promoter to increase its transcription. Enhancers are relatively orientation and position independent having been found 5' (Laimins et al., Proc. Natl. Acad. Sci. USA, 78: 993 [1981]) and 3' (Lusky et al., Mol. Cell Bio., 3: 1108 [1983]) to the transcription unit, within an intron (Banerji et al., Cell, 33: 729 [1983]) as well as within the coding sequence itself (Osborne et al., Mol. Cell Bio., 4: 1293 [1984]). Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α -fetoprotein and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication

origin, and adenovirus enhancers. See also Yaniv, Nature, 297: 17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5' or 3' to the PF4AR DNA, but is preferably located at a site 5' from the promoter.

(vi) Transcription Termination Component

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the PF4AR. The 3' untranslated regions also include transcription termination sites.

Suitable vectors containing one or more of the above listed components and the desired coding and control sequences are constructed by standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required.

For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform *E. coli* K12 strain 294 (ATCC 31,446) and successful transformants selected by ampicillin or tetracycline resistance where appropriate. Plasmids from the transformants are prepared, analyzed by restriction endonuclease digestion, and/or sequenced by the method of Messing et al., Nucleic Acids Res., 9: 309 (1981) or by the method of Maxam et al., Methods in Enzymology, 65: 499 (1980).

Particularly useful in the practice of this invention are expression vectors that provide for the transient expression in mammalian cells of DNA encoding the PF4AR. In general, transient expression involves the use of an expression vector that is able to

replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expression vector. Transient expression systems, comprising a suitable expression vector and a host cell, allow for the convenient positive identification of polypeptides encoded by cloned DNAs, as well as for the rapid screening of such polypeptides for desired biological or physiological properties. Thus, transient expression systems are particularly useful in the invention for purposes of identifying analogs and variants of the PF4AR that have PF4AR-like activity.

Other methods, vectors, and host cells suitable for adaptation to the synthesis of the PF4AR in recombinant vertebrate cell culture are described in Gething et al., Nature, 293: 620-625 (1981); Mantei et al., Nature, 281: 40-46 (1979); Levinson et al., EP 117,060; and EP 117,058. A particularly useful plasmid for mammalian cell culture expression of the PF4AR is pRK5 (EP pub. no. 307,247) or pSVI6B (PCT pub. no. WO 91/08291 published 13 June 1991).

D. Selection and Transformation of Host Cells

Suitable host cells for cloning or expressing the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, *E. coli*, *Bacilli* such as *B. subtilis*, *Pseudomonas* species such as *P. aeruginosa*, *Salmonella typhimurium*, or *Serratia marcescens*. One preferred *E. coli* cloning host is *E. coli* 294 (ATCC 31,446), although other strains such as *E. coli* B, *E. coli* χ 1776 (ATCC 31,537), and *E. coli* W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting. Preferably the host cell should secrete minimal amounts of proteolytic enzymes. Alternatively, *in vitro* methods of cloning, e.g. PCR or other nucleic acid polymerase reactions, are suitable.

5 In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable hosts for vectors containing PF4AR DNA. *Saccharomyces cerevisiae*, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and useful herein, such as *S. pombe* (Beach and Nurse, Nature, 290: 140 [1981]), *Kluyveromyces lactis* (Louvencourt et al., J. Bacteriol., 737 [1983]), *yarrowia* (EP 402,226), *Pichia pastoris* (EP 183,070), *Trichoderma reesia* (EP 244,234), *Neurospora crassa* (Case et al., Proc. Natl. Acad. Sci. USA, 76: 5259-5263 [1979]), and *Aspergillus* hosts such as *A. nidulans* (Ballance et al., Biochem. Biophys. Res. Commun., 112: 284-289 [1983]; Tilburn et al., Gene, 26: 205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and *A. niger* (Kelly and Hynes, EMBO J., 4: 475-479 [1985]).

15
20
25
30
Suitable host cells for the expression of glycosylated PF4AR polypeptide are derived from multicellular organisms. Such host cells are capable of complex processing and glycosylation activities. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosophila melanogaster* (fruitfly), and *Bombyx mori* host cells have been identified. See, e.g., Luckow et al., Bio/Technology, 6: 47-55 (1988); Miller et al., in Genetic Engineering, Setlow, J.K. et al., 8: 277-279 (Plenum Publishing, 1986), and Maeda et al., Nature, 315: 592-594 (1985). A variety of such viral strains are publicly available, e.g., the L-1 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV, and such viruses may be used as the virus herein according to the

present invention, particularly for transfection of *Spodoptera frugiperda* cells.

Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as hosts. Typically, plant cells are transfected by incubation with certain strains of the bacterium *Agrobacterium tumefaciens*, which has been previously manipulated to contain the PF4AR DNA. During incubation of the plant cell culture with *A. tumefaciens*, the DNA encoding PF4AR is transferred to the plant cell host such that it is transfected, and will, under appropriate conditions, express the PF4AR DNA. In addition, regulatory and signal sequences compatible with plant cells are available, such as the nopaline synthase promoter and polyadenylation signal sequences. Depicker et al., J. Mol. Appl. Gen., 1: 561 (1982). In addition, DNA segments isolated from the upstream region of the T-DNA 780 gene are capable of activating or increasing transcription levels of plant-expressible genes in recombinant DNA-containing plant tissue. See EP 321,196 published 21 June 1989.

However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure in recent years [Tissue Culture, Academic Press, Kruse and Patterson, editors (1973)]. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol., 36: 59 (1977); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216 [1980]); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23: 243-251 [1980]); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human

lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci., 383: 44-68 [1982]); MRC 5 cells; FS4 cells; and a human hepatoma cell line (Hep G2). Preferred host cells are human embryonic kidney 293 and Chinese hamster ovary cells.

Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

Transfection refers to the taking up of an expression vector by a host cell whether or not any coding sequences are in fact expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for example, CaPO_4 and electroporation. Successful transfection is generally recognized when any indication of the operation of this vector occurs within the host cell.

Transformation means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integrant. Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in section 1.82 of Sambrook et al., *supra*, is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23: 315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method described in sections 16.30-16.37 of Sambrook et al., *supra*, is preferred. General aspects of mammalian cell host system transformations have been described by Axel in U.S. 4,399,216 issued 16 August 1983. Transformations into yeast are typically carried out according to the method of Van Solingen et

al., J. Bact., 130: 946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76: 3829 (1979). However, other methods for introducing DNA into cells such as by nuclear injection, electroporation, or by protoplast fusion may also be used.

5 E. Culturing the Host Cells

Prokaryotic cells used to produce the PF4AR polypeptide of this invention are cultured in suitable media as described generally in Sambrook et al., *supra*.

10 The mammalian host cells used to produce the PF4AR of this invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ([MEM], Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ([DMEM], Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham and Wallace, Meth. Enz., 58: 44 (1979), Barnes and Sato, Anal. Biochem., 102: 255 (1980), U.S. 4,767,704; 4,657,866; 4,927,762; or 4,560,655; WO 90/03430; WO 87/00195; U.S. Pat. Re. 30,985; or U.S. 5,122,469, the disclosures of all of which are incorporated herein by reference, may be used as culture media for the host cells. Any of these
15 media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as GentamycinTM drug), trace
20 elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as
25 temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
30

The host cells referred to in this disclosure encompass cells in *in vitro* culture as well as cells that are within a host animal.

It is further envisioned that the PF4AR of this invention may be produced by homologous recombination, or with recombinant production methods utilizing control elements introduced into cells already containing DNA encoding the PF4AR. For example, a powerful promoter/enhancer element, a suppressor, or an exogenous transcription modulatory element is inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA encoding the desired PF4AR. The control element does not encode the PF4AR of this invention, but the DNA is present in the host cell genome. One next screens for cells making the PF4AR of this invention, or increased or decreased levels of expression, as desired.

F. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, northern blotting to quantitate the transcription of mRNA (Thomas, Proc. Natl. Acad. Sci. USA, 77: 5201-5205 [1980]), dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Various labels may be employed, most commonly radioisotopes, particularly ³²P. However, other techniques may also be employed, such as using biotin-modified nucleotides for introduction into a polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, which may be labeled with a wide variety of labels, such as radionuclides, fluorescers, enzymes, or the like. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex

on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. With immunohistochemical staining techniques, a cell sample is prepared, typically by dehydration and fixation, followed by reaction with labeled antibodies specific for the gene product coupled, where the labels are usually visually detectable, such as enzymatic labels, fluorescent labels, luminescent labels, and the like. A particularly sensitive staining technique suitable for use in the present invention is described by Hsu et al., Am. J. Clin. Path., 75: 734-738 (1980).

Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native PF4AR polypeptide or against a synthetic peptide based on the DNA sequences provided herein as described further in Section 4 below.

G. Purification of The PF4AR Polypeptide

The PF4AR is recovered from the culture cells by solubilizing cell membrane in detergent.

When a human PF4AR is expressed in a recombinant cell other than one of human origin, the PF4AR is completely free of proteins or polypeptides of human origin. However, it is necessary to purify the PF4AR from recombinant cell proteins or polypeptides to obtain preparations that are substantially homogeneous as to the PF4AR. As a first step, the cells are centrifuged to separate them from culture medium. The membrane and soluble protein fractions are then separated. The PF4AR may then be purified from the membrane fraction of the culture lysate by solubilization with detergents followed by suitable purification procedures:

fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; hydrophobic affinity resins and ligand affinity using the appropriate PF4A immobilized on a matrix.

PF4AR variants in which residues have been deleted, inserted or substituted are recovered in the same fashion as the native PF4AR, taking account of any substantial changes in properties occasioned by the variation. For example, preparation of a PF4AR fusion with another protein or polypeptide, e.g. a bacterial or viral antigen, facilitates purification; an immunoaffinity column containing antibody to the antigen can be used to adsorb the fusion. Immunoaffinity columns such as a rabbit polyclonal anti-PF4AR column can be employed to absorb the PF4AR variant by binding it to at least one remaining immune epitope. A protease inhibitor such as phenyl methyl sulfonyl fluoride (PMSF) also may be useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent the growth of adventitious contaminants. One skilled in the art will appreciate that purification methods suitable for native PF4AR may require modification to account for changes in the character of the PF4AR or its variants upon expression in recombinant cell culture.

H. Covalent Modifications of PF4AR Polypeptides

Covalent modifications of PF4AR polypeptides are included within the scope of this invention. Both native PF4ARs and amino acid sequence variants of the PF4AR may be covalently modified. Covalent modifications of the PF4AR, fragments thereof or antibodies thereto are introduced into the molecule by reacting targeted amino acid residues of the PF4AR, fragments thereof, or PF4AR antibody with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues. Most commonly, PF4AR and its antibodies are covalently

bonded to detectable groups used in diagnosis, e.g. enzymes, radio isotopes, spin labels, antigens, fluorescent or chemiluminescent groups and the like.

Cysteiny1 residues most commonly are reacted with α -haloacetates (and corresponding amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Cysteiny1 residues also are derivatized by reaction with bromotrifluoroacetone, α -bromo- β -(5-imidazole)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.

Histidyl residues are derivatized by reaction with diethylpyrocarbonate at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain. Para-bromophenacyl bromide also is useful; the reaction is preferably performed in 0.1M sodium cacodylate at pH 6.0.

Lysiny1 and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. Derivatization with these agents has the effect of reversing the charge of the lysiny1 residues. Other suitable reagents for derivatizing α -amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione; and transaminase-catalyzed reaction with glyoxylate.

Arginy1 residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pK_a of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.

The specific modification of tyrosyl residues may be made, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidazole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Tyrosyl residues are iodinated using ^{125}I or ^{131}I to prepare labeled proteins for use in radioimmunoassay, the chloramine T method described above being suitable.

Carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with carbodiimides ($\text{R}'\text{-N}=\text{C}=\text{N-R}'$), where R and R' are different alkyl groups, such as 1-cyclohexyl-3-(2-morpholinyl-4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

Derivatization with bifunctional agents is useful for crosslinking PF4AR, its fragments or antibodies to a water-insoluble support matrix or surface for use in methods for purifying anti-PF4AR antibodies, and vice versa. Immobilized PF4AR also is useful in screening for the PF4 superfamily members to which the receptor binds. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azido-salicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidyl-propionate), and bifunctional maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents such as methyl-3-[(p-azidophenyl)-dithio]propioimide yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates

described in U.S. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.

Glutaminy and asparaginy residues are frequently deamidated to the corresponding glutamyl and aspartyl residues, respectively. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.

Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the α -amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 [1983]), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the beta-8 polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. By altering is meant deleting one or more carbohydrate moieties found in the native receptor, and/or adding one or more glycosylation sites that are not present in the native receptor.

Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tri-peptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tri-peptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose, to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. As noted

above, the IL-8 receptor contains 6 putative N-linked glycosylation sites.

5 Addition of glycosylation sites to the PF4AR polypeptide is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tri-peptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the native PF4AR sequence (for O-linked glycosylation sites). For ease, the PF4AR amino acid
10 sequence is preferably altered through changes at the DNA level, particularly by mutating the DNA encoding the PF4AR polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids. The DNA mutation(s) may be made using methods described above under the heading of "Amino Acid Sequence Variants of PF4AR Polypeptide".
15

Another means of increasing the number of carbohydrate moieties on the PF4AR polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. These procedures are advantageous in that they do not require production of the polypeptide in a host cell that has glycosylation capabilities for N- and O- linked glycosylation. Depending on the coupling mode used, the sugar(s) may be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine. These methods are described in WO 87/05330 published 11 September 1987, and in Aplin and Wriston (CRC Crit. Rev. Biochem., pp. 259-306 [1981]).
20
25

30 Removal of carbohydrate moieties present on the native PF4AR polypeptide may be accomplished chemically or enzymatically. Chemical deglycosylation requires exposure of the polypeptide to the compound trifluoromethanesulfonic acid, or an equivalent

compound. This treatment results in the cleavage of most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. Chemical deglycosylation is described by Hakimuddin et al., Arch. Biochem. Biophys., 259: 52 (1987) and by Edge et al., Anal. Biochem., 118: 131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138: 350 (1987).

Glycosylation at potential glycosylation sites may be prevented by the use of the compound tunicamycin as described by Duskin et al., J. Biol. Chem., 257: 3105 (1982). Tunicamycin blocks the formation of protein-N-glycoside linkages.

The PF4AR also may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-[methylmethacrylate] microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A., Ed., (1980).

PF4AR preparations are also useful in generating antibodies, for use as standards in assays for the PF4AR (e.g. by labeling the PF4AR for use as a standard in a radioimmunoassay, enzyme-linked immunoassay, or radioreceptor assay), in affinity purification techniques, and in competitive-type receptor binding assays when labeled with radioiodine, enzymes, fluorophores, spin labels, and the like.

Since it is often difficult to predict in advance the characteristics of a variant PF4AR, it will be appreciated that some screening of the recovered variant will be needed to select the optimal variant. For example, a change in the immunological

character of the PF4AR molecule, such as affinity for a given antibody, is measured by a competitive-type immunoassay. The variant is assayed for changes in the suppression or enhancement of its activity by comparison to the activity observed for native PF4AR in the same assay. Other potential modifications of protein or polypeptide properties such as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation, or the tendency to aggregate with carriers or into multimers are assayed by methods well known in the art.

3. Therapeutic Compositions and Administration of PF4AR

Therapeutic formulations of PF4AR (including its PF4AR binding fragments) or antibodies thereto are prepared for storage by mixing PF4AR having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences, supra), in the form of lyophilized cake or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronic or polyethylene glycol (PEG).

The PF4AR, or antibody to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution. The PF4AR ordinarily will be stored in lyophilized form or in solution.

Therapeutic PF4AR or antibody compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

5 The route of PF4AR or antibody administration is in accord with known methods, e.g. injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, or intralesional routes, or by sustained release systems as noted below. Preferably the antibody is given
10 systemically.

Suitable examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices include
15 polyesters, hydrogels, polylactides (U.S. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., Biopolymers, 22: 547-556 [1983]), poly (2-hydroxyethyl-methacrylate) (Langer et al., J. Biomed. Mater. Res., 15: 167-277 [1981] and Langer, Chem. Tech., 12: 98-105 [1982]), ethylene vinyl acetate (Langer et al., *supra*) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release PF4AR or antibody compositions
20 also include liposomally entrapped PF4AR or antibody. Liposomes containing PF4AR or antibody are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA, 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese patent application 83-118008; U.S. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. % cholesterol, the selected
25 proportion being adjusted for the optimal PF4AR or antibody therapy.

30 An "effective amount" of PF4AR or antibody to be employed therapeutically will depend, for example, upon the therapeutic

objectives, the route of administration, the type of PF4AR polypeptide or antibody employed, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. Typically, the clinician will administer the PF4AR or antibody until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays.

In the treatment and prevention of an inflammatory disorder by a PF4AR antibody, particularly an IL-8 receptor antibody, the antibody composition will be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the antibody, the particular type of antibody, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The "therapeutically effective amount" of antibody to be administered will be governed by such considerations, and is the minimum amount necessary to prevent, ameliorate, or treat the inflammatory disorder, including treating chronic respiratory diseases and reducing inflammatory responses. Such amount is preferably below the amount that is toxic to the host or renders the host significantly more susceptible to infections.

As a general proposition, the initial pharmaceutically effective amount of the antibody administered parenterally per dose will be in the range of about 0.1 to 50 mg/kg of patient body weight per day, with the typical initial range of antibody used being 0.3 to 20 mg/kg/day, more preferably 0.3 to 15 mg/kg/day.

As noted above, however, these suggested amounts of antibody are subject to a great deal of therapeutic discretion. The key

factor in selecting an appropriate dose and scheduling is the result obtained, as indicated above.

The antibody need not be, but is optionally formulated with one or more agents currently used to prevent or treat the inflammatory disorder in question. For example, in rheumatoid arthritis, the antibody may be given in conjunction with a glucocorticosteroid. In addition, T cell receptor peptide therapy is suitably an adjunct therapy to prevent clinical signs of autoimmune encephalomyelitis. Offner et al., *supra*. The effective amount of such other agents depends on the amount of PF4AR antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore employed dosages.

4. PF4AR Antibody Preparation

Polyclonal antibodies to the PF4AR generally are raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the PF4AR and an adjuvant. Immunization with recombinant cells transformed with the PF4AR (e.g., 293, mouse, or CHO cells transformed with huPF4AR) may be satisfactory, or it may be useful to separate the PF4AR and conjugate it or a fragment containing the target amino acid sequence to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl_2 , or $\text{R}^1\text{N} = \text{C} = \text{NR}$, where R and R^1 are different alkyl groups.

Animals ordinarily are immunized against the transfected cells, or immunogenic conjugates, derivatives, or peptides every other week. 7 to 14 days after the immunization the animals are bled and the serum is assayed for anti-PF4AR titer. Preferably,

the animal is boosted with the conjugate of the same PF4AR, but conjugated to a different protein and/or through a different cross-linking agent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response. Less preferably, the animals are immunized by combining 1 mg or 1 μ g of PF4AR in Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. 7 to 14 days later the animals are bled and the serum is assayed for anti-PF4AR titer. Animals are boosted until the titer plateaus.

Another option is to employ combinatorial variable domain libraries and screening methods to identify the desired anti-PF4AR antibodies.

Monoclonal antibodies are prepared by recovering spleen cells from immunized animals and immortalizing the cells in conventional fashion, e.g. by fusion with myeloma cells or by Epstein-Barr (EB)-virus transformation and screening for clones expressing the desired antibody.

The monoclonal antibody preferably is specific for each target PF4AR polypeptide, and will not cross-react with rabbit fMLP receptor (Thomas et al., J. Biol. Chem., *supra*), human fMLP receptor, human C5a receptor the low affinity IL-8 receptor, or other members of the PF4AR family. Antibodies specific for the receptor of Figs. 2, 4 or 5 are preferred. The antibody is selected to be either agonistic, antagonistic, or to have no effect on the activity of a PF4 super-family member in binding to or activating the receptor.

Murphy and Tiffany, *supra*, describe a receptor having a high degree of homology to the receptor of Fig. 2. Murphy and Tiffany characterized their receptor in recombinant oocytes as being a receptor for IL-8 and having capability to bind MGSA, thus

5 suggesting that it plays a minor role in IL-8 and MGSA biological activity *in vivo*. The studies herein, however, have shown that the Murphy and Tiffany receptor exhibits IL-8 affinity as high or higher than the receptor of Fig. 2 and that as well it shows high affinity (about 1-10nM) for MGSA. Thus, antagonism of the IL-8 and/or MGSA response of lymphoid cells will likely require that both receptors be inhibited or blocked. For example, one should select an IL-8 antagonist antibody that binds to an epitope of the Fig. 2 receptor that is shared by the Murphy and Tiffany receptor. This could be readily accomplished by routine screening methods. For example, the candidate antibodies can be assayed for their ability to compete against labelled IL-8 for binding to cells bearing the Fig. 2 receptor, and then the same study conducted with cells bearing the Murphy and Tiffany receptor. Antibodies that inhibit IL-8 activation or binding to both cells are then selected as therapeutic candidates. On the other hand, antibodies that can discriminate between the Fig. 2 and Murphy and Tiffany receptors and bind only to one or the other are useful in diagnosis. The receptor of Fig. 2 binds MGSA poorly, in contrast to the Murphy and Tiffany receptor.

5. Uses of PF4AR its nucleic acid and its Antibodies

The nucleic acid encoding the PF4AR may be used as a diagnostic for tissue specific typing. For example, such procedures as *in situ* hybridization, and northern and Southern blotting, and PCR analysis may be used to determine whether DNA and/or RNA encoding the PF4AR are present in the cell type(s) being evaluated. These receptors typically are diagnostic of PBL or monocytic cells.

Isolated PF4AR polypeptide may be used in quantitative diagnostic assays as a standard or control against which samples e.g. from PBL or monocytic cells, containing unknown quantities of PF4AR may be compared. Recombinant cells which express the IL-8 receptor can be used in assays for PF4A ligands in the same fashion

as for example neutrophils are used in IL-8 assays. The PF4AR polypeptides, fragments or cells (as such, or derivatized) also can be used as immunogens in the production of antibodies to PF4AR, for the purification of such antibodies from ascites or recombinant cell culture media or for use as competitive anatagonists for superfamily ligands, e.g. IL-8.

The PF4AR are useful in screening for amino acid sequence or other variants of PF4 superfamily members. For example, a bank of candidate IL-8 amino acid sequence variants are prepared by site directed mutagenesis. These are incubated in competition with labelled native IL-8 for cells bearing the IL-8 receptor of Fig. 2 in order identify agonist or antagonist IL-8 variants. Binding or cell activation are suitable assay endpoints. Alternatively, the receptor is recovered in cell-free form and binding of IL-8 and candidate variants assayed.

PF4AR antibodies are useful in diagnostic assays for PF4AR expression in specific cells or tissues wherein the antibodies are labeled in the same fashion as the PF4AR described above and/or are immobilized on an insoluble matrix. PF4AR antibodies also are useful for the affinity purification of the PF4AR from recombinant cell culture or natural sources. The PF4AR antibodies that do not detectably cross-react with other PF4ARs can be used to purify each PF4AR free from other homologous receptors. PF4AR antibodies that are PF4 antagonists are useful as anti-inflammatory agents or in the treatment of other PF4 superfamily-mediated disorders.

Suitable diagnostic assays for the PF4AR and its antibodies are well known *per se*. Such assays include competitive and sandwich assays, and steric inhibition assays. Competitive and sandwich methods employ a phase-separation step as an integral part of the method while steric inhibition assays are conducted in a single reaction mixture. Fundamentally, the same procedures are used for the assay of the PF4AR and for substances that bind the PF4AR, although certain methods will be favored depending upon the

imidates, bis-diazotized benzidine, and the like may be used to tag the antibodies with the above-described fluorescent, chemiluminescent, and enzyme labels. See, for example, U.S. Pat. Nos. 3,940,475 (fluorimetry) and 3,645,090 (enzymes); Hunter et al., Nature, 144: 945 (1962); David et al., Biochemistry, 13: 1014-1021 (1974); Pain et al., J. Immunol. Methods, 40: 219-230 (1981); and Nygren, J. Histochem. and Cytochem., 30: 407-412 (1982). Preferred labels herein are enzymes such as horseradish peroxidase and alkaline phosphatase.

The conjugation of such label, including the enzymes, to the antibody is a standard manipulative procedure for one of ordinary skill in immunoassay techniques. See, for example, O'Sullivan et al., "Methods for the Preparation of Enzyme-antibody Conjugates for Use in Enzyme Immunoassay," in Methods in Enzymology, ed. J.J. Langone and H. Van Vunakis, Vol. 73 (Academic Press, New York, New York, 1981), pp. 147-166. Such binding methods are suitable for use with PF4AR or its antibodies, all of which are proteinaceous.

Immobilization of reagents is required for certain assay methods. Immobilization entails separating the binding partner from any analyte that remains free in solution. This conventionally is accomplished by either insolubilizing the binding partner or analyte analogue before the assay procedure, as by adsorption to a water-insoluble matrix or surface (Bennich et al., U.S. 3,720,760), by covalent coupling (for example, using glutaraldehyde cross-linking), or by insolubilizing the partner or analogue afterward, e.g., by immunoprecipitation.

Other assay methods, known as competitive or sandwich assays, are well established and widely used in the commercial diagnostics industry.

Competitive assays rely on the ability of a tracer analogue to compete with the test sample analyte for a limited number of binding sites on a common binding partner. The binding partner generally is insolubilized before or after the competition and then

the tracer and analyte bound to the binding partner are separated from the unbound tracer and analyte. This separation is accomplished by decanting (where the binding partner was preinsolubilized) or by centrifuging (where the binding partner was precipitated after the competitive reaction). The amount of test sample analyte is inversely proportional to the amount of bound tracer as measured by the amount of marker substance. Dose-response curves with known amounts of analyte are prepared and compared with the test results to quantitatively determine the amount of analyte present in the test sample. These assays are called ELISA systems when enzymes are used as the detectable markers.

Another species of competitive assay, called a "homogeneous" assay, does not require a phase separation. Here, a conjugate of an enzyme with the analyte is prepared and used such that when anti-analyte binds to the analyte the presence of the anti-analyte modifies the enzyme activity. In this case, the PF4AR or its immunologically active fragments are conjugated with a bifunctional organic bridge to an enzyme such as peroxidase. Conjugates are selected for use with anti-PF4AR so that binding of the anti-PF4AR inhibits or potentiates the enzyme activity of the label. This method *per se* is widely practiced under the name of EMIT.

Steric conjugates are used in steric hindrance methods for homogeneous assay. These conjugates are synthesized by covalently linking a low-molecular-weight hapten to a small analyte so that antibody to hapten substantially is unable to bind the conjugate at the same time as anti-analyte. Under this assay procedure the analyte present in the test sample will bind anti-analyte, thereby allowing anti-hapten to bind the conjugate, resulting in a change in the character of the conjugate hapten, e.g., a change in fluorescence when the hapten is a fluorophore. Sandwich assays particularly are useful for the determination of PF4AR or PF4AR antibodies. In sequential sandwich assays an immobilized binding

partner is used to adsorb test sample analyte, the test sample is removed as by washing, the bound analyte is used to adsorb labeled binding partner, and bound material is then separated from residual tracer. The amount of bound tracer is directly proportional to test sample analyte. In "simultaneous" sandwich assays the test sample is not separated before adding the labeled binding partner. A sequential sandwich assay using an anti-PF4AR monoclonal antibody as one antibody and a polyclonal anti-PF4AR antibody as the other is useful in testing samples for PF4AR activity.

The foregoing are merely exemplary diagnostic assays for PF4AR and antibodies. Other methods now or hereafter developed for the determination of these analytes are included within the scope hereof, including the bioassays described above.

The polypeptides set forth in Figs. 4 and 5 are believed to represent receptors for different and as yet undetermined members of the PF4 superfamily (which includes both the C-C and CXC subfamilies). Like the IL-8 receptor of Fig. 2 they are members of the G-protein-coupled superfamily and bear greater similarity to the IL-8 receptor than other receptors. In preliminary experiments, recombinant cells bearing these receptors do not respond to Rantes, MCP1, IL-8 or MGSA, although they may ultimately be shown to bind other members of the PF4 superfamily or presently unknown ligands. However, whether or not the Figs. 4 or 5 polypeptides bind to members of the PF4 superfamily, the polypeptides are useful for preparing antibodies for diagnostic use in determining the tissue distribution of the receptors and thus as an immunohistochemical diagnostic for such tissues, in particular as a diagnostic for monocytic cells or PBLs since it is known that such cells express the receptors of Figs. 4 and 5. Of course, once the PF4 superfamily members are identified which bind to these receptors then the receptors can be used to diagnose the presence of the identified members or for their purification in specific affinity procedures. The DNA in Figs. 4 and 5 also is useful in

diagnostics for the presence of DNA or RNA encoding the IL-8 receptor when low stringency conditions are employed.

All references cited in this specification are expressly incorporated by reference.

The following examples are offered by way of illustration and not by way of limitation.

EXAMPLE 1

To obtain the clone PRK5B.il8r1.1, a cDNA (Gubler and Hoffman, Gene, 25: 263-269 [1983]) library of 1,000,000 clones was constructed from human neutrophil mRNA (Chirgwin et al., Biochem., 18: 5294-5299 [1979]) in the vector pRK5B using BstXI linkers. The cDNA is produced in blunted form. Hemi-kinase bstXI linkers are ligated to the CDNA, and the linkers ligated into the PRK5B vector that had been bstXI digested, phosphatased, and the long vector fragment isolated. PRK5B is a derivative of PRK5 (EP 307,247) that contains a cytomegalovirus promoter followed by a 5' intron, bstXI cloning site, and an SV40 early polyadenylation signal, although it will be understood that any mammalian cell expression vector will be satisfactory, 58 pools of 2500 clones each were transfected into COS-7 cells by electroporation (Gearing et al., *supra*) of 20 µg of DNA into 3,750,000 cells After 2 days of growth on 150-mm dishes in medium (50:50::Ham's F12:DMEM) containing 10 % fetal calf serum, ¹²⁵I-IL-8 binding was performed. Purified human 72 amino acid IL-8 made in E. coli (Hébert et al., J. Immunology, 145: 3033-3040 [1990]) was labeled by the lactoperoxidase method (Morrison and Bayse, Biochem., 2: 2995-3000 [1970]) to about 1100 Ci/mmol and was at least 85 % bindable. Dishes were rinsed twice with phosphate-buffered saline, and binding was performed with 8 ml per dish of growth medium containing 2.5 % fetal calf serum and about 0.5 nM ¹²⁵I-IL-8. After 2 hr at 37°C, the plates were rinsed three times with phosphate-buffered saline, the bottoms cut out (Pacholczyk et al., BioTechniques, 2: 556-558 [1990]), and autoradiographed. Each

positive pool of 2500 cDNA clones was subsequently partitioned into pools of 800 clones, and each of these was transfected and assayed. Each positive pool in turn was subdivided through pools of 185, 30 and finally a single clone(s) until single positive clones were identified to obtain the pure isolate. Since only a portion of each pool was used for transfection it was unnecessary to rescue clones from transformants.

Binding competition was performed with electroporated COS-7 cells after 1 day of expression in 6-well dishes (about 175,000 cells/dish). Binding was performed with radioiodinated wild type IL-8 in binding medium Ca^{2+} and Mg^{2+} -free Hanks buffered with 25 mM Hepes and supplemented with 0.5% bovine serum albumin [BSA]) at 4°C for about 2 hr. Wells were then washed, the cells harvested with trypsin, and counted. No specific binding was found in parallel wells containing cells transfected with DNA from the vector pRK5B. Neutrophil binding was performed as described (Pacholczyk et al., *supra*) but for 2 hr at 4°C.

EXAMPLE 2

Existing λ gt10 cDNA libraries from the human cell line, HL60, and from human peripheral blood lymphocytes were screened at low stringency with a probe from the coding region of the cloned high-affinity human IL-8 receptor (Fig. 2). The probe was the 874 bp PstI/NcoI fragment of the receptor containing the coding region for amino acids 23-314. Hybridization was in 20% formamide, 4 x SSC, 50 mM sodium phosphate buffer, pH 7, 0.2 g/l sonicated salmon sperm DNA, 5 x Denhardts, 10% dextran sulfate, at 42°C with a wash at 1 x SSC, 0.1% SDS at 50°C. A number of duplicate spots of varying intensity (about 60) were picked, plaque purified, subcloned into plasmid vectors, and sequenced. Nucleic acid sequencing began with the selection of spots of greatest intensity. Sufficient sequence was obtained for a given spot (phage) to determine whether or not evidence of structural or sequence homology with the IL-8 receptor

existed. If it did, then the remainder of the gene was obtained (if necessary) and sequenced in its entirety.

To avoid sequences all hybridizing clone the sequence was then used to probe the parental collection of IL-8 receptor DNA hybridizing clones under high stringency conditions in order to identify and discard other spots containing the same hybridizing gene. This technique was highly effective in reducing the sequencing burden. For example, one clone was represented by about one third of the initial 60 clones, and on this result alone the negative screen was able to reduce considering the work involved in sequencing the clones.

From this screen, two new gene sequences were found that are clearly related to the IL-8 receptor. The coding region for one new gene was split between two clones (8rr.20 and 8rr.15). The combined sequence of this gene (8rr.20.15) is shown in Figure 4. The complete coding region for the second gene is found on clone 8rr.9 (Figure 5). The predicted amino acid sequence of 8rr.20.15 is 34% identical with both the high and low affinity IL-8 receptor sequences. The sequence of 8rr.9 is 36% and 38% identical with the high and low affinity IL-8 receptor sequences, respectively (Holmes et al., *Science*, 253: 1278 [1991] and Murphy and Tiffany, *supra*). The amino acid sequence of 8rr.20.15 and 8rr.9 are 31% identical. Use of this probe under low stringency conditions did not produce detectable hybridization to the fMLP receptor genes that were expected to be found in these libraries.

EXAMPLE 3

Monoclonal antibodies to IL-8 type A receptor were generated by immunizing mice with synthetic peptides corresponding to various extracellular domains of IL8R-A or with stably transfected cells expressing IL8R-A, respectively. Blocking and non-blocking monoclonal antibodies were identified and their binding sites were

mapped to the N-terminal region of IL8R-A. Details are provided below:

Experimental Protocol

Recombinant human IL-8 (rHuIL-8) was produced in *E. coli* and purified as described in Hébert et al., *supra*.

For generating IL8R-A-bearing cells, human fetal kidney 293 cells were co-transfected with pRK5B.il8r1.1 (Holmes et al., *supra*) or pRK5.8rr27-1.1 (Lee et al., *J. Biol. Chem.*, 267: 16283-16287 [1992]) and pSVENeoBal6 (Seeburg et al., *Nature*, 312: 71-75 [1984]) plasmids in a 10:1 molar ratio, using a CaPO₄ precipitation method as described in Gorman in DNA Cloning: A Practical Approach, ed., Glover, D.M. (IRL: Oxford, 1984), Vol. 2, pp. 143-165. Transfected cells were selected in F12/DMEM (50:50) media containing 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 µg/ml penicillin, and 100 µg/ml streptomycin. Forty G418-resistant clonal lines were isolated from the pRK5B.il8r1.1 transfection. The IL8R-A-bearing transfected cells were selected by their ability to bind to ¹²⁵I-IL-8, and clone 293-71 was used for further study. Thirty G418-resistant clonal lines were isolated from the pRK5.8rr.27-1.1 transfection. After the ¹²⁵I-IL-8 binding experiment, clone 36 was selected for further study.

Mutants were prepared by the method of Kunkel, *Proc. Natl. Acad. Sci. USA*, 82: 488 (1985) using the *dut- ung-* strain of *E. coli* CJ236 and a pUC-derived vector containing a cDNA insert coding for the IL-8 receptor A: pRK5B.IL-8r1.1. Holmes et al., *supra*. After verification of the mutant DNA sequence with the Sequenase™ version 2.0 kit (U.S. Biochemical Corp.), the mutated plasmid preparations were purified with the Qiagen™ plasmid maxi kit (Qiagen Inc., Chatsworth, CA) and used to transfect 293 cells by the calcium phosphate precipitate method of Gorman, *supra*. The cell cultures were incubated for seven hours in the presence of mutant or wild-type DNA precipitate (10 µg DNA/100 mm dish). The precipitate was then removed and the cells were cultured for an

additional 17 hours prior to fluorescence-activated cell sorter (FACS) analysis.

Peptides were synthesized via solid-phase methodology (Barany and Merrifield, in "the peptides," 2: 1-284, Gross and Meienhofer, eds, [Academic Press: New York, 1980]) on either an ABI model 430 peptide synthesizer using tert-butyloxycarbonyl (t-BOC) chemistry or a Milligen model 9050 and ABI model 431 peptide synthesizer using fluorenylmethyloxycarbonyl (Fmoc) chemistry. Crude peptides were purified by high-pressure liquid chromatography (HPLC) and analyzed via mass spectrometry. Peptides were conjugated to soybean trypsin inhibitor using m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (Sulfo-MBS) (Pierce Co., Rockford, IL).

BALB/c mice were immunized intraperitoneally with 10 µg of synthetic peptides covering various portions of extracellular domains of IL8R-A conjugated to horse serum albumin or 10⁶ cells/100 µl of 293-71 transfected cells, resuspended in MPL/TDM (Ribi Immunochem. Research Inc., Hamilton, MT) and boosted nine times with the same amount of peptides or 16 times with transfected cells. Three days after the final boost with the antigen, spleen cells were fused with mouse myeloma P3X63Ag8U.1 (Yelton et al., Curr. Top. Microbiol. Immunol., 81: 1-7 [1978]), a non-secreting clone of the myeloma P3X63Ag8 (Kohler and Milstein, Nature, 256: 495 [1975]) using 35% polyethylene glycol as described by Laskov et al., Cell. Immunol., 55: 251-264 (1980). Ten days after the fusion, culture supernatants were screened for the presence of monoclonal antibodies to IL8R-A by an ELISA or FACS.

Nunc™ brand 96-well immunoplates (Flow Lab, McLean, VA) were coated with 50 µl/well of 2 µg/mL IL8R-A synthetic peptide in phosphate buffered saline (PBS) overnight at 4°C. The remaining steps were carried out at room temperature as described by Kim et al., J. Imm. Methods., 156: 9 (1992). The isotypes of monoclonal antibodies were determined by coating the plates with IL8R-A

peptides overnight, blocked with 0.2% BSA, incubated with culture supernatants, followed by the addition of a predetermined amount of isotype-specific alkaline phosphatase-conjugated goat anti-mouse Ig (Fisher Biotech, Pittsburgh, PA). The level of conjugated antibodies that bound to the plate was determined by the addition of p-nitrophenyl phosphate substrate in carbonate buffer containing 1 mM of $MgCl_2$ (Sigma 104 phosphate substrate, Sigma, St. Louis, MO). The color reaction was measured at 405 nm with an ELISA plate reader (Titertrek multiscan, Flow Lab, McLean, VA).

Human neutrophils were prepared by using Mono-Poly Resolving medium (M-PRM) (Flow Lab, McLean, VA) according to the vendor's direction. Neutrophils or transfected cells were washed twice in the cell sorter buffer (CSB, PBS containing 1% FCS and 0.02% NaN_3) at 300 x g for 5 minutes. Twenty-five μl of cells (4×10^6 cells/ml) were added into a 96-well U-bottom microtiter plate, mixed with 100 μl of culture supernatant or purified monoclonal antibodies, and incubated for 30 min. on ice. After washing, cells were incubated with 100 μl of FITC-conjugated goat-anti-mouse IgG antibodies for 30 min. at 4°C. Cells were washed twice in CSB and resuspended in 150 μl of CSB and analyzed by a FCAScan™ assay (Becton-Dickinson).

The affinity of the monoclonal antibodies was determined by competitive inhibition of the binding of ^{125}I -monoclonal antibody to 293-71-transfected cells with various concentrations of unlabeled monoclonal antibodies. ^{125}I -monoclonal antibodies were prepared by using chloramine-T as described by Lee et al., *supra*. The specific activities of monoclonal antibodies 6C8, 6E9, 2A4, and 9H1 were 0.68 Ci/M, 0.74 Ci/M, 0.814 Ci/M, and 0.922 Ci/M, respectively. Fifty μl of 293-17 (4×10^6 cells/ml) resuspended in Hank's buffered saline solution (HBSS) containing 0.5% BSA, were briefly incubated with 100 μl of a fixed concentration of ^{125}I -monoclonal antibody plus 50 μl of various concentrations of unlabeled monoclonal antibody for one hour at 4°C. The unbound ^{125}I -monoclonal antibody was

removed by centrifugation of the mixture over 0.5 ml of PBS containing 20% sucrose and 0.5% BSA at 1,500 rpm for five minutes. The ^{125}I -monoclonal antibody bound to the cell pellet was determined using a gamma counter. The affinity of each monoclonal antibody was determined by using Scatplot™ analysis. Munson and Rodbard, Anal. Biochem., 107: 220 (1980).

The blocking ability of the monoclonal antibodies was determined by measuring their effects on the interaction of IL-8 with IL8R-A. Fifty μl of human neutrophils or transfected cells (4×10^6 cells/ml) resuspended in the HBSS medium containing 0.5% BSA and 25 mM HEPES buffer were incubated with 50 μl of monoclonal antibodies plus various concentrations of MGSA (0-0.5 nM) for one hour at 4°C. Cells were washed twice in the HBSS medium and resuspended to be 1×10^6 cells/ml. One hundred μl of cells were incubated with 100 μl of ^{125}I -IL-8 (1 Ci/M) for one hour at 4°C and the unbound ^{125}I -IL-8 was removed using 20% sucrose as described above. The ^{125}I -IL-8 bound to the cell pellets was counted using a gamma counter.

Results

General Characteristics of the antibodies.

For generation of monoclonal antibodies to IL8R-A, mice were immunized either with synthetic peptides corresponding to various extracellular domains of IL8R-A or with stably transfected cells expressing IL8R-A.

For the first approach, eight peptides were synthesized covering the extracellular domains of IL8R-A, residues 2-19 and 12-31 located within the N-terminal portion of IL8R-A, 99-110 within the first loop, 176-186 and 187-203 within the second loop, and 265-277 and 277-291 within the third loop as shown in Fig. 6. All of these peptides induced high-titer antibodies to each peptide in mice. However, only peptide 2-19 produced polyclonal antibodies that were able to recognize human neutrophils as well as 293-71-transfected cells expressing IL8R-A. The mice immunized with

peptide 2-19 were used to generate 36 hybridomas secreting monoclonal antibodies to peptide 2-19. Only two of these monoclonal antibodies (4C8 and 6E9) were able to recognize IL8R-A on 293-transfected cells and were selected for further characterization.

In a second approach, mice were immunized with 293-71 cells producing IL8R-A (293-71). Positive antibody titers were detected only after the 16th immunization. These mice were used to obtain more than 60 positive hybridomas that secreted monoclonal antibodies recognizing IL8R-A on 293-71 cells, as determined by FACS. Two out of 60 monoclonal antibodies, 2A4 and 9H1, were able to inhibit the binding of ^{125}I -IL-8 to its receptors and were chosen for further evaluation.

These four hybridomas secrete IgG1 immunoglobulin isotype (Table 2). Monoclonal antibodies 2A4 and 9H1, generated using transfected cells, have higher affinities than monoclonal antibodies 4C8 and 6E9, generated using peptides (Table 2). All four monoclonal antibodies were able to bind to human neutrophils and 293-71-transfected cells but not to 293 parent cells, as determined by FACS analysis (Figure 7). Thus, it was concluded that all these monoclonal antibodies were capable of recognizing native IL8R-A.

Table 2

	<u>Mab</u>	<u>Immunogen</u>	<u>Isotype</u>	<u>FACS Analysis</u>		<u>K_d</u> <u>(nM)</u>
				<u>293-71</u>	<u>Neutrophil</u>	
5	4C8	Peptide 2-19	IgG1	+	+	3.26
	6E9	Peptide 2-19	IgG1	+	+	17.26
10	2A4	293-71	IgG1	+	+	0.44
	9H1	293-71	IgG1	+	+	0.088

Cross reactivities to other related receptors.

15 It has been shown that IL-8 specific receptor, IL8R-A, shares
 77% amino acid identity with IL8R-B, the common IL-8/MGSA receptor.
 For determining whether monoclonal antibodies generated to IL8R-A
 could recognize IL8R-B, 293 cells transfected with IL8R-B were
 stained and analyzed by FACS (Fig. 7). All four monoclonal
 20 antibodies stained the IL8R-A 293-transfected cells, but not the
 IL8R-B-transfected 293 cells. The inability of these monoclonal
 antibodies to bind to 293 cells expressing IL8R-B was not due to
 the lack of receptor expression, since the same level of ¹²⁵I-IL-8
 was bound to IL8R-A expressing transfected cells, as well as to the
 25 IL8R-B expressing transfected cells.

Inhibition of IL-8 binding to IL8R-A.

The effect of the monoclonal antibodies on the binding of ¹²⁵I-
 IL-8 to the 293-71-transfected cells expressing IL8R-A (Fig. 8) was
 investigated. Monoclonal antibodies 2A4 and 9H1 could completely
 30 block the ¹²⁵I-IL-8 binding to the 293-71 cells, whereas monoclonal
 antibodies 4C8 and 6E9 showed very minimal effect.

It was further investigated whether monoclonal antibodies 2A4
 and 9H1 could block IL-8 binding onto human neutrophils in the
 presence of various concentrations of MGSA, known to bind to IL8R-
 35 B. The addition of 475 pM of MGSA inhibited approximately 50% of
 IL-8 binding to human neutrophils (Fig. 8). In the presence of 475

5 pM of MGSA, monoclonal antibodies 2A4 and 9H1 could block up to 80% of the IL-8 binding to human neutrophils, while the control monoclonal antibody showed no further inhibition beyond that observed with MGSA alone. Thus, it was concluded that monoclonal antibodies 2A4 and 9H1 could block the binding of IL-8 to IL8R-A on human neutrophils.

Epitope mapping of the IL8R-A specific monoclonal antibodies.

10 The epitopes recognized by these monoclonal antibodies were mapped by investigating the binding of these antibodies to synthetic peptides by ELISA (Fig. 9A and 9B) and alanine mutants of IL8R-A by FACS (Table 3). Surprisingly, both blocking and non-blocking monoclonal antibodies bound to the N-terminal peptide consisting of amino acids 2-19, but did not bind to other peptides covering different portions of extracellular loops of the receptor (Fig. 9A).

15 The binding of monoclonal antibodies to shorter peptides consisting of residues 1-11 and 1-14 in ELISA is shown in Figure 9B. All four monoclonal antibodies bound well to peptide 1-14. However, the binding of the blocking monoclonal antibodies, 2A4 and 20 9H1, to peptide 1-11 was only 22% and 60% of the binding to peptide 2-19, respectively. In contrast, the binding of the non-blocking monoclonal antibodies 4C8 and 6E9 to peptide 1-11 was approximately 80% and 95% of the binding to peptide 2-19, respectively. From these results, it was concluded that epitopes of monoclonal 25 antibodies 4C8 and 6E9 are localized within amino acids 2-11, while those of monoclonal antibodies 2A4 and 9H1 are localized within amino acids 2-14.

Table 3

Flow Cytometry Analysis of Antibodies with Cells
Expressing Mutant IL-8 Type A Receptor

<u>Amino Acid Position</u>	<u>Change</u>		<u>FACS Analysis</u>			
	<u>From</u>	<u>To</u>	<u>2A4</u>	<u>9H1</u>	<u>4C8</u>	<u>6E9</u>
6	D	A	-	-	+	+
11	D	A	++	++	+	+
13-14	DD	A	++	++	+	++
24-26	DED	AAA	++	++	++	+

FACS Result: - (mean FL channel 0-10), + (Mean FL channel 10-100, ++ (Mean FL channel 100-1000).

A (Alanine), D (Aspartic acid), K (Lysine), E (Glutamic Acid)

The binding epitopes of these monoclonal antibodies were further investigated by analyzing their binding to IL8R-A mutants by FACS (Table 3). Neither monoclonal antibody 2A4 nor 9H1 could bind to the IL8R-A mutant when the aspartic acid at position 6 was substituted with alanine, suggesting Asp6 plays an important role in the binding of these blocking antibodies. This result further suggests that the conformation of the N-terminal end of the IL8R-A may play a role in the binding of these blocking monoclonal antibodies.

Conclusion

IL-8 is a potent neutrophil chemotactic factor and has been implicated as a key mediator of neutrophil influx in many inflammatory diseases. IL-8 has been detected in many biological fluids from patients with a variety of acute and chronic inflammatory diseases such as arthritis, emphysema, cystic fibrosis, ulcerative colitis, chronic bronchitis, and

bronchiectasis. Koch et al., J. Immunol., 147: 2187-2195 (1991); Koch et al., Science, 258: 1798-1801 (1992); Terkeltaub et al., Arthr. and Rheum., 34: 894 (1991); Mahida et al., Clin. Science, 82: 273-275 (1992); Broaddus et al., Am. Rev. Resp., 146: 825 (1992). In vitro neutralization of the IL-8 in these biological fluids significantly reduces the overall chemotactic activity in the fluid. Further, the role of IL-8 is implicated in inflammatory conditions where the cellular infiltrate is predominantly neutrophil-rich, including gout, rheumatoid arthritis, adult respiratory distress syndrome, emphysema, glomerular nephritis, myocardial infarction, inflammatory bowel disease, and asthma. Lindley et al., Adv. Exp. Med., 305: 147-156 (1991). However, to what extent IL-8 contributes to inflammation *in vivo* has yet to be determined.

Various monoclonal antibodies directed against IL-8 have been defined, including those reported by Sticherling et al., J. Immunol., 143: 1628-1634 (1989).

It is anticipated that an antagonist to IL8R-A will be more effective in blocking the effect of IL-8 function *in vivo* than an antagonist to IL-8 for the following reasons: IL-8 is relatively long-lasting and resistant to proteases, possibly making it difficult to block IL-8 completely *in vivo*, the IL8R-A expression is dynamically regulated by the ligand itself, and the rapid recycling of IL-8 receptors may be essential for the chemotactic response of neutrophils and tissue damage during inflammation, caused by activated neutrophils. Thus, monoclonal antibodies to IL8R-A expressed on human neutrophils were generated with the ultimate goal of identifying neutralizing monoclonal antibodies that could be tested as receptor antagonists of various inflammation in *in vivo* models.

The antibody responses to different extracellular portions of IL8R-A were induced using several synthetic peptides covering the extracellular domains of IL8R-A or IL8R-A-transfected cells as

immunogens. Both methods of immunization allowed generation of monoclonal antibodies recognizing IL8R-A on human neutrophils (Figure 6). It was much harder to generate monoclonal antibodies specific for IL8R-A by using transfected cells as an immunogen; however, monoclonal antibodies generated using transfected cells tended to have higher affinities to IL8R-A and showed blocking activities.

Polyclonal antibody responses were able to be induced to all seven peptides covering the extracellular domains of IL8R-A, residues 2-19, 12-31, 99-110, 176-186, 187-203, 265-277, and 277-291. However, only the polyclonal antibodies to peptide 2-19 recognize IL8R-A on cells. This suggests that the N-terminal amino acids may be the most immunogenic or that the most likely immunogenic sites have conformational epitopes.

A 77% sequence identity between IL8R-A and IL8R-B was reported by Holmes *et al.*, *supra*; however, the antibodies herein were specific for IL8R-A. IL8R-A does not recognize IL-1, TNF- α , MCAF, fMLP, C5 α , PAF, and LTB₄, but does recognize two other members of the C-X-C family, namely, MGSA and NAP-2. Holmes *et al.*, *supra*. A recent study shows that both receptors bind IL-8 equally well with a high affinity but differ in their affinity to MGSA. Murphy and Tiffany, *supra*. Monoclonal antibodies 2A4 and 9H1 block 100% of the IL-8 binding to transfected 293 cells, 35-40% of the IL-8 binding to human neutrophils, and approximately 80% of IL-8 binding to human neutrophils in the presence of MGSA, which presumably blocked IL-8 binding to IL8R-B. Thus, the blocking monoclonal antibodies herein interfere with the interaction between IL-8 and IL8R-A, but not with the interaction between IL-8 and IL8R-B. Both monoclonal antibodies 4C8 and 6E9 showed no blocking activities in IL-8 binding to both transfected cells and human neutrophils.

The finding that both blocking and non-blocking monoclonal antibodies bind to the N-terminal amino acid residues 1-14 (Fig. 9A) is consistent with the report that the N-terminal amino acid

sequence of IL8R-A plays an important role in interacting with IL-8. Gayle et al., J. Biol. Chem., 268: 7283-7289 (1993). Further epitope mapping analysis showed some differences in the binding characteristics between blocking and non-blocking monoclonal antibodies. The epitopes of blocking monoclonal antibodies 2A4 and 9H1 were mapped within residues 2-14 of the receptor, while those of non-blocking monoclonal antibodies 4C8 and 6E9 were within 2-11 amino acid residues. The binding study using various alanine mutants shows that the aspartic acid at position 6 plays an important role in the binding of the blocking monoclonal antibodies, but not of the non-blocking monoclonal antibodies. This suggests that this negatively charged aspartic acid may be located at (or near to) the binding site of IL-8. It has been shown that positively charged IL-8 residues E₄, L₅, R₆ are essential for IL-8 binding to its receptors on human neutrophils by alanine-scanning mutagenesis (Hébert et al., J. Biol. Chem., 266: 18989-18994 [1991]) and synthesis of N-terminal truncated variants (Clark-Lewis et al., J. Biol. Chem., 266: 23128-23134 [1991]; Moser et al., J. Biol. Chem., 268: 7125-7128 [1993]). Without being limited to any one theory, it is believed that the negatively charged amino acid at position 6 in IL8R-A is in a direct or close interaction with the positively charged amino acids, E₄, L₅, R₆ in IL-8, so that the binding of blocking monoclonal antibodies is influenced by the tertiary structure of the receptor.

The N-terminal portion and the second extracellular portion of the IL8R-A appears to be highly glycosylated, especially within amino acids 2-19 of the receptor, where there are six potential glycosylation sites (Fig. 6). However, all of the monoclonal antibodies herein, whether generated by immunization of synthetic peptides or of transfected cells, bound to the synthetic peptide covering amino acids 1-14. This suggests that carbohydrates may not play an important role in the binding of these monoclonal antibodies.

EXAMPLE 4

IL-8 was found to be present at high concentration and is the major neutrophil chemotactic factor in sputum from patients with chronic bronchitis, bronchiectasis, and cystic fibrosis. Figure 10 shows the concentration of IL-8 in sputum from patients with chronic airway diseases and in sputum induced from healthy patients.

An ELISA is developed to measure rabbit IL-8 concentration using a double monoclonal antibody technique where one antibody is used as the coat and the other is the biotinylated detection antibody. In the assay buffer the sensitivity is < 12 pg/ml (linear range 12-1000 pg/ml). In 10% rabbit serum the sensitivity is 14 pg/ml (linear range 14-1000 pg/ml).

One of the two antibodies 2A4 and 9H1 described above is injected intravenously every two weeks in a dose of 1-15 mg/kg in patients having either asthma, chronic bronchitis, bronchiectasis, rheumatoid arthritis, or ulcerative colitis. For treating an acute indication, adult respiratory distress syndrome, a dose of 10-100 mg/kg of either one of the antibodies is injected a single time intravenously. It would be expected that the anti-IL8R-A antibodies that block IL8R-A activity (MAbs 2A4 and 9H1) would be effective in reducing the inflammation associated with each of the disorders described above. The antibodies are also expected to be efficacious in treating human pleurisy, vasculitis, alveolitis, and pneumonia.

Deposit of Materials

The following hybridomas have been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA (ATCC):

<u>Cell Lines</u>	<u>ATCC Accession No.</u>	<u>Deposit Date</u>
2A4	HB 11377	June 8, 1993
9H1	HB 11376	June 8, 1993

These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable deposit for 30 years from the date of deposit. These cell lines will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the cell lines to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the cell lines to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC §122 and the Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638).

The assignee of the present application has agreed that if the deposited cell lines should be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a specimen of the same cell line. Availability of the deposited cell lines is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the cell lines deposited, since the deposited embodiments are intended as illustrations of one aspect of the invention and any cell lines that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as

limiting the scope of the claims to the specific illustrations that
it represents. Indeed, various modifications of the invention in
addition to those shown and described herein will become apparent
to those skilled in the art from the foregoing description and fall
5 within the scope of the appended claims.

09404053 062498

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Chuntharapai, Anan
 Lee, James
 Hebert, Caroline
 K. Jin Kim

(ii) TITLE OF INVENTION: Antibodies to Human PF4A Receptors

(iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Genentech, Inc.
 (B) STREET: 460 Point San Bruno Blvd
 (C) CITY: South San Francisco
 (D) STATE: California
 (E) COUNTRY: USA
 (F) ZIP: 94080

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: patin (Genentech)

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
 (B) FILING DATE: 11-JUN-1993
 (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 07/810
 (B) FILING DATE: 19-DEC-1991

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 782
 (B) FILING DATE: 29-MAR-1991

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 07/677
 (B) FILING DATE: (null)

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 211
 (B) FILING DATE: (null)

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Hasak, Janet E.

(B) REGISTRATION NUMBER: 28,616
(C) REFERENCE/DOCKET NUMBER: 706P2

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 415/225-1896
(B) TELEFAX: 415/952-9881
(C) TELEX: 910/371-7168

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1933 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCTGGCCGGT GCTTCAGTTA GATCAAACCA TTGCTGAAAC TGAAGAGGAC 50

ATG TCA AAT ATT ACA GAT CCA CAG ATG TGG GAT TTT 86
Met Ser Asn Ile Thr Asp Pro Gln Met Trp Asp Phe
1 5 10

GAT GAT CTA AAT TTC ACT GGC ATG CCA CCT GCA GAT GAA 125
Asp Asp Leu Asn Phe Thr Gly Met Pro Pro Ala Asp Glu
15 20 25

GAT TAC AGC CCC TGT ATG CTA GAA ACT GAG ACA CTC AAC 164
Asp Tyr Ser Pro Cys Met Leu Glu Thr Glu Thr Leu Asn
30 35

AAG TAT GTT GTG ATC ATC GCC TAT GCC CTA GTG TTC CTG 203
Lys Tyr Val Val Ile Ile Ala Tyr Ala Leu Val Phe Leu
40 45 50

CTG AGC CTG CTG GGA AAC TCC CTG GTG ATG CTG GTC ATC 242
Leu Ser Leu Leu Gly Asn Ser Leu Val Met Leu Val Ile
55 60

TTA TAC AGC AGG GTC GGC CGC TCC GTC ACT GAT GTC TAC 281
Leu Tyr Ser Arg Val Gly Arg Ser Val Thr Asp Val Tyr
65 70 75

CTG CTG AAC CTG GCC TTG GCC GAC CTA CTC TTT GCC CTG 320
Leu Leu Asn Leu Ala Leu Ala Asp Leu Leu Phe Ala Leu
80 85 90

	ACC	TTG	CCC	ATC	TGG	GCC	GCC	TCC	AAG	GTG	AAT	GGC	TGG	359
	Thr	Leu	Pro	Ile	Trp	Ala	Ala	Ser	Lys	Val	Asn	Gly	Trp	
					95					100				
5	ATT	TTT	GGC	ACA	TTC	CTG	TGC	AAG	GTG	GTC	TCA	CTC	CTG	398
	Ile	Phe	Gly	Thr	Phe	Leu	Cys	Lys	Val	Val	Ser	Leu	Leu	
		105					110					115		
10	AAG	GAA	GTC	AAC	TTC	TAC	AGT	GGC	ATC	CTG	CTG	TTG	GCC	437
	Lys	Glu	Val	Asn	Phe	Tyr	Ser	Gly	Ile	Leu	Leu	Leu	Ala	
				120					125					
15	TGC	ATC	AGT	GTG	GAC	CGT	TAC	CTG	GCC	ATT	GTC	CAT	GCC	476
	Cys	Ile	Ser	Val	Asp	Arg	Tyr	Leu	Ala	Ile	Val	His	Ala	
	130					135					140			
20	ACA	CGC	ACA	CTG	ACC	CAG	AAG	CGT	CAC	TTG	GTC	AAG	TTT	515
	Thr	Arg	Thr	Leu	Thr	Gln	Lys	Arg	His	Leu	Val	Lys	Phe	
			145					150					155	
25	GTT	TGT	CTT	GGC	TGC	TGG	GGA	CTG	TCT	ATG	AAT	CTG	TCC	554
	Val	Cys	Leu	Gly	Cys	Trp	Gly	Leu	Ser	Met	Asn	Leu	Ser	
					160					165				
30	CTG	CCC	TTC	TTC	CTT	TTC	CGC	CAG	GCT	TAC	CAT	CCA	AAC	593
	Leu	Pro	Phe	Phe	Leu	Phe	Arg	Gln	Ala	Tyr	His	Pro	Asn	
		170					175					180		
35	AAT	TCC	AGT	CCA	GTT	TGC	TAT	GAG	GTC	CTG	GGA	AAT	GAC	632
	Asn	Ser	Ser	Pro	Val	Cys	Tyr	Glu	Val	Leu	Gly	Asn	Asp	
				185					190					
40	ACA	GCA	AAA	TGG	CGG	ATG	GTG	TTG	CGG	ATC	CTG	CCT	CAC	671
	Thr	Ala	Lys	Trp	Arg	Met	Val	Leu	Arg	Ile	Leu	Pro	His	
	195					200					205			
45	ACC	TTT	GGC	TTC	ATC	GTG	CCG	CTG	TTT	GTC	ATG	CTG	TTC	710
	Thr	Phe	Gly	Phe	Ile	Val	Pro	Leu	Phe	Val	Met	Leu	Phe	
			210					215					220	
50	TGC	TAT	GGA	TTC	ACC	CTG	CGT	ACA	CTG	TTT	AAG	GCC	CAC	749
	Cys	Tyr	Gly	Phe	Thr	Leu	Arg	Thr	Leu	Phe	Lys	Ala	His	
					225					230				
55	ATG	GGG	CAG	AAG	CAC	CGA	GCC	ATG	AGG	GTC	ATC	TTT	GCT	788
	Met	Gly	Gln	Lys	His	Arg	Ala	Met	Arg	Val	Ile	Phe	Ala	
		235					240					245		
60	GTC	GTC	CTC	ATC	TTC	CTG	CTT	TGC	TGG	CTG	CCC	TAC	AAC	827
	Val	Val	Leu	Ile	Phe	Leu	Leu	Cys	Trp	Leu	Pro	Tyr	Asn	

				250					255					
5	CTG	GTC	CTG	CTG	GCA	GAC	ACC	CTC	ATG	AGG	ACC	CAG	GTG	866
	Leu	Val	Leu	Leu	Ala	Asp	Thr	Leu	Met	Arg	Thr	Gln	Val	
	260					265					270			
10	ATC	CAG	GAG	ACC	TGT	GAG	CGC	CGC	AAC	AAC	ATC	GGC	CGG	905
	Ile	Gln	Glu	Thr	Cys	Glu	Arg	Arg	Asn	Asn	Ile	Gly	Arg	
			275					280					285	
15	GCC	CTG	GAT	GCC	ACT	GAG	ATT	CTG	GGA	TTT	CTC	CAT	AGC	944
	Ala	Leu	Asp	Ala	Thr	Glu	Ile	Leu	Gly	Phe	Leu	His	Ser	
					290					295				
20	TGC	CTC	AAC	CCC	ATC	ATC	TAC	GCC	TTC	ATC	GGC	CAA	AAT	983
	Cys	Leu	Asn	Pro	Ile	Ile	Tyr	Ala	Phe	Ile	Gly	Gln	Asn	
		300					305					310		
25	TTT	CGC	CAT	GGA	TTC	CTC	AAG	ATC	CTG	GCT	ATG	CAT	GGC	1022
	Phe	Arg	His	Gly	Phe	Leu	Lys	Ile	Leu	Ala	Met	His	Gly	
				315					320					
30	CTG	GTC	AGC	AAG	GAG	TTC	TTG	GCA	CGT	CAT	CGT	GTT	ACC	1061
	Leu	Val	Ser	Lys	Glu	Phe	Leu	Ala	Arg	His	Arg	Val	Thr	
	325					330					335			
35	TCC	TAC	ACT	TCT	TCG	TCT	GTC	AAT	GTC	TCT	TCC	AAC	CTC	1100
	Ser	Tyr	Thr	Ser	Ser	Ser	Val	Asn	Val	Ser	Ser	Asn	Leu	
			340					345					350	
40	TGAAAACCAT CGATGAAGGA ATATCTCTTC TCAGAAGGAA AGAATAACCA 1150													
45	ACACCCTGAG GTTGTGTGTG GAAGGTGATC TGGCTCTGGA CAGGCACTAT 1200													
50	CTGGGTTTTG GGGGGACGCT ATAGGATGTG GGGAAGTTAG GAACTGGTGT 1250													
55	CTTCAGGGGC CACACCAACC TTCTGAGGAG CTGTTGAGGT ACCTCCAAGG 1300													
60	ACCGGCCTTT GCACCTCCAT GGAAACGAAG CACCATCATT CCCGTTGAAC 1350													
65	GTCACATCTT TAACCCACTA ACTGGCTAAT TAGCATGGCC ACATCTGAGC 1400													
70	CCCGAATCTG ACATTAGATG AGAGAACAGG GCTGAAGCTG TGTCCTCATG 1450													

AGGGCTGGAT GCTCTCGTTG ACCCTCACAG GAGCATCTCC TCAACTCTGA 1500

GTGTTAAGCG TTGAGCCACC AAGCTGGTGG CTCTGTGTGC TCTGATCCGA 1550

GCTCAGGGGG GTGGTTTTTC CATCTCAGGT GTGTTGCAGT GTCTGCTGGA 1600

GACATTGAGG CAGGCACTGC CAAAACATCA ACCTGCCAGC TGGCCTTGTG 1650

AGGAGCTGGA AACACATGTT CCCCTTGGGG GTGGTGGATG AACAAAGAGA 1700

AAGAGGGTTT GGAAGCCAGA TCTATGCCAC AAGAACCCCC TTTACCCCCA 1750

TGACCAACAT CGCAGACACA TGTGCTGGCC ACCTGCTGAG CCCCAAGTGG 1800

AACGAGACAA GCAGCCCTTA GCCCTTCCCC TCTGCAGCTT CCAGGCTGGC 1850

GTGCAGCATC AGCATCCCTA GAAAGCCATG TGCAGCCACC AGTCCATTGG 1900

GCAGGCAGAT GTTCCTAATA AAGCTTCTGT TCC 1933

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1737 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GAATTCCAGT GTGCTGGCGG CGCGGCGCAA AGTGACGCCG AGGGCCTGAG 50

TGCTCCAGTA GCCACCGCAT CTGGAGAACC AGCGGTTACC ATG GAG 96
Met Glu
1

GGG ATC AGT ATA TAC ACT TCA GAT AAC TAC ACC GAG GAA 135

Gly Ile Ser Ile Tyr Thr Ser Asp Asn Tyr Thr Glu Glu
 5 10 15
 5 ATG GGC TCA GGG GAC TAT GAC TCC ATG AAG GAA CCC TGT 174
 Met Gly Ser Gly Asp Tyr Asp Ser Met Lys Glu Pro Cys
 20 25
 10 TTC CGT GAA GAA AAT GCT AAT TTC AAT AAA ATC TTC CTG 213
 Phe Arg Glu Glu Asn Ala Asn Phe Asn Lys Ile Phe Leu
 30 35 40
 15 CCC ACC ATC TAC TCC ATC ATC TTC TTA ACT GGC ATT GTG 252
 Pro Thr Ile Tyr Ser Ile Ile Phe Leu Thr Gly Ile Val
 45 50
 20 GGC AAT GGA TTG GTC ATC CTG GTC ATG GGT TAC CAG AAG 291
 Gly Asn Gly Leu Val Ile Leu Val Met Gly Tyr Gln Lys
 55 60 65
 25 AAA CTG AGA AGC ATG ACG GAC AAG TAC AGG CTG CAC CTG 330
 Lys Leu Arg Ser Met Thr Asp Lys Tyr Arg Leu His Leu
 70 75 80
 30 TCA GTG GCC GAC CTC CTC TTT GTC ATC ACG CTT CCC TTC 369
 Ser Val Ala Asp Leu Leu Phe Val Ile Thr Leu Pro Phe
 85 90
 35 TGG GCA GTT GAT GCC GTG GCA AAC TGG TAC TTT GGG AAC 408
 Trp Ala Val Asp Ala Val Ala Asn Trp Tyr Phe Gly Asn
 95 100 105
 40 TTC CTA TGC AAG GCA GTC CAT GTC ATC TAC ACA GTC AAC 447
 Phe Leu Cys Lys Ala Val His Val Ile Tyr Thr Val Asn
 110 115
 45 CTC TAC AGC AGT GTC CTC ATC CTG GCC TTC ATC AGT CTG 486
 Leu Tyr Ser Ser Val Leu Ile Leu Ala Phe Ile Ser Leu
 120 125 130
 50 GAC CGC TAC CTG GCC ATC GTC CAC GCC ACC AAC AGT CAG 525
 Asp Arg Tyr Leu Ala Ile Val His Ala Thr Asn Ser Gln
 135 140 145
 55 AGG CCA AGG AAG CTG TTG GCT GAA AAG GTG GTC TAT GTT 564
 Arg Pro Arg Lys Leu Leu Ala Glu Lys Val Val Tyr Val
 150 155
 60 GGC GTC TGG ATC CCT GCC CTC CTG CTG ACT ATT CCC GAC 603
 Gly Val Trp Ile Pro Ala Leu Leu Leu Thr Ile Pro Asp
 160 165 170

	TTC	ATC	TTT	GCC	AAC	GTC	AGT	GAG	GCA	GAT	GAC	AGA	TAT	642
	Phe	Ile	Phe	Ala	Asn	Val	Ser	Glu	Ala	Asp	Asp	Arg	Tyr	
				175					180					
5	ATC	TGT	GAC	CGC	TTC	TAC	CCC	AAT	GAC	TTG	TGG	GTG	GTT	681
	Ile	Cys	Asp	Arg	Phe	Tyr	Pro	Asn	Asp	Leu	Trp	Val	Val	
	185					190					195			
10	GTG	TTC	CAG	TTT	CAG	CAC	ATC	ATG	GTT	GGC	CTT	ATC	CTG	720
	Val	Phe	Gln	Phe	Gln	His	Ile	Met	Val	Gly	Leu	Ile	Leu	
			200					205					210	
15	CCT	GGT	ATT	GTC	ATC	CTG	TCC	TGC	TAT	TGC	ATT	ATC	ATC	759
	Pro	Gly	Ile	Val	Ile	Leu	Ser	Cys	Tyr	Cys	Ile	Ile	Ile	
					215					220				
20	TCC	AAG	CTG	TCA	CAC	TCC	AAG	GGC	CAC	CAG	AAG	CGC	AAG	798
	Ser	Lys	Leu	Ser	His	Ser	Lys	Gly	His	Gln	Lys	Arg	Lys	
		225					230					235		
25	GCC	CTC	AAG	ACC	ACA	GTC	ATC	CTC	ATC	CTG	GCT	TTC	TTC	837
	Ala	Leu	Lys	Thr	Thr	Val	Ile	Leu	Ile	Leu	Ala	Phe	Phe	
				240					245					
30	GCC	TGT	TGG	CTG	CCT	TAC	TAC	ATT	GGG	ATC	AGC	ATC	GAC	876
	Ala	Cys	Trp	Leu	Pro	Tyr	Tyr	Ile	Gly	Ile	Ser	Ile	Asp	
	250					255					260			
35	TCC	TTC	ATC	CTC	CTG	GAA	ATC	ATC	AAG	CAA	GGG	TGT	GAG	915
	Ser	Phe	Ile	Leu	Leu	Glu	Ile	Ile	Lys	Gln	Gly	Cys	Glu	
			265					270					275	
40	TTT	GAG	AAC	ACT	GTG	CAC	AAG	TGG	ATT	TCC	ATC	ACC	GAG	954
	Phe	Glu	Asn	Thr	Val	His	Lys	Trp	Ile	Ser	Ile	Thr	Glu	
					280					285				
45	GCC	CTA	GCT	TTC	TTC	CAC	TGT	TGT	CTG	AAC	CCC	ATC	CTC	993
	Ala	Leu	Ala	Phe	Phe	His	Cys	Cys	Leu	Asn	Pro	Ile	Leu	
		290					295					300		
50	TAT	GCT	TTC	CTT	GGA	GCC	AAA	TTT	AAA	ACC	TCT	GCC	CAG	1032
	Tyr	Ala	Phe	Leu	Gly	Ala	Lys	Phe	Lys	Thr	Ser	Ala	Gln	
				305					310					
55	CAC	GCA	CTC	ACC	TCT	GTG	AGC	AGA	GGG	TCC	AGC	CTC	AAG	1071
	His	Ala	Leu	Thr	Ser	Val	Ser	Arg	Gly	Ser	Ser	Leu	Lys	
	315					320					325			
60	ATC	CTC	TCC	AAA	GGA	AAG	CGA	GGT	GGA	CAT	TCA	TCT	GTT	1110
	Ile	Leu	Ser	Lys	Gly	Lys	Arg	Gly	Gly	His	Ser	Ser	Val	

330

335

340

TCC ACT GAG TCT GAG TCT TCA AGT TTT CAC TCC AGC TAAC 1150
 Ser Thr Glu Ser Glu Ser Ser Ser Phe His Ser Ser
 345 350 352

ACAGATGTAA AAGACTTTTT TTTATACGAT AAATAACTTT TTTTAAAGTT 1200

ACACATTTTT CAGATATAAA AGACTGACCA ATATTGTACA GTTTTTATTG 1250

CTTGTTGGAT TTTTGTCTTG TGTTTCTTTA GTTTTTGTGA AGTTTAATTG 1300

ACTTATTTAT ATAAATTTTT TTTGTTTCAT ATTGATGTGT GTCTAGGCAG 1350

GACCTGTGGC CAAGTTCTTA GTTGCTGTAT GTCTCGTGGT AGGACTGTAG 1400

AAAAGGGAAC TGAACATTCC AGAGCGTGTA GTGAATCACG TAAAGCTAGA 1450

AATGATCCCC AGCTGTTTAT GCATAGATAA TCTCTCCATT CCCGTGGAAC 1500

GTTTTTCCTG TTCTTAAGAC GTGATTTTGC TGTAGAAGAT GGCACCTATA 1550

ACCAAAGCCC AAAGTGGTAT AGAAATGCTG GTTTTTTCAGT TTTCAGGAGT 1600

GGGTTGATTT CAGCACCTAC AGTGTACAGT CTTGTATTAA GTTGTTAATA 1650

AAAGTACATG TTAAACTTAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1700

AAAAAAAAAA AAAGCGGCCG CCAGCACACT GGAATTC 1737

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1679 bases

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

5 GAATTCCAGT GTGCTGGCGG CCGCCCAGTG TGCTGGCGGC GGCAGTTGAG 50

10 GGAAAGGACA GAGGTTATGA GTGCCTGCAA GAGTGGCAGC CTGGAGTAGA 100

15 GAAAACACTA AAGGTGGAGT CAAAAGACCT GAGTTCAAGT CCCAGCTCTG 150

20 CCACTGGTTA GCTGTGGGAT CTCGGAAAAG ACCCAGTGAA AAAAAAAAAA 200

25 AAAGTGATGA GTTGTGAGGC AGGTCGCGGC CCTACTGCCT CAGGAGACGA 250

30 TGCGCAGCTC ATTTGCTTAA ATTTGCAGCT GACGGCTGCC ACCTCTCTAG 300

35 AGGCACCTGG CGGGGAGCCT CTCAACATAA GACAGTGACC AGTCTGGTGA 350

40 CTCACAGCCG GCACAGCC ATG AAC TAC CCG CTA ACG CTG GAA 392
Met Asn Tyr Pro Leu Thr Leu Glu
1 5

45 ATG GAC CTC GAG AAC CTG GAG GAC CTG TTC TGG GAA CTG 431
Met Asp Leu Glu Asn Leu Glu Asp Leu Phe Trp Glu Leu
10 15 20

50 GAC AGA TTG GAC AAC TAT AAC GAC ACC TCC CTG GTG GAA 470
Asp Arg Leu Asp Asn Tyr Asn Asp Thr Ser Leu Val Glu
25 30

55 AAT CAT CTC TGC CCT GCC ACA GAG GGG CCC CTC ATG GCC 509
Asn His Leu Cys Pro Ala Thr Glu Gly Pro Leu Met Ala
35 40 45

60 TCC TTC AAG GCC GTG TTC GTG CCC GTG GCC TAC AGC CTC 548
Ser Phe Lys Ala Val Phe Val Pro Val Ala Tyr Ser Leu
50 55 60

65 ATC TTC CTC CTG GGC GTG ATC GGC AAC GTC CTG GTG CTG 587
Ile Phe Leu Leu Gly Val Ile Gly Asn Val Leu Val Leu
65 70

70 GTG ATC CTG GAG CGG CAC CGG CAG ACA CGC AGT TCC ACG 626
Val Ile Leu Glu Arg His Arg Gln Thr Arg Ser Ser Thr

75

80

85

GAG ACC TTC CTG TTC CAC CTG GCC GTG GCC GAC CTC CTG 665
Glu Thr Phe Leu Phe His Leu Ala Val Ala Asp Leu Leu
90 95

CTG GTC TTC ATC TTG CCC TTT GCC GTG GCC GAG GGC TCT 704
Leu Val Phe Ile Leu Pro Phe Ala Val Ala Glu Gly Ser
100 105 110

GTG GGC TGG GTC CTG GGG ACC TTC CTC TGC AAA ACT GTG 743
Val Gly Trp Val Leu Gly Thr Phe Leu Cys Lys Thr Val
115 120 125

ATT GCC CTG CAC AAA GTC AAC TTC TAC TGC AGC AGC CTG 782
Ile Ala Leu His Lys Val Asn Phe Tyr Cys Ser Ser Leu
130 135

CTC CTG GCC TGC ATC GCC GTG GAC CGC TAC CTG GCC ATT 821
Leu Leu Ala Cys Ile Ala Val Asp Arg Tyr Leu Ala Ile
140 145 150

GTC CAC GCC GTC CAT GCC TAC CGC CAC CGC CGC CTC CTC 860
Val His Ala Val His Ala Tyr Arg His Arg Arg Leu Leu
155 160

TCC ATC CAC ATC ACC TGT GGG ACC ATC TGG CTG GTG GGC 899
Ser Ile His Ile Thr Cys Gly Thr Ile Trp Leu Val Gly
165 170 175

TTC CTC CTT GCC TTG CCA GAG ATT CTC TTC GCC AAA GTC 938
Phe Leu Leu Ala Leu Pro Glu Ile Leu Phe Ala Lys Val
180 185 190

AGC CAA GGC CAT CAC AAC AAC TCC CTG CCA CGT TGC ACC 977
Ser Gln Gly His His Asn Asn Ser Leu Pro Arg Cys Thr
195 200

TTC TCC CAA GAG AAC CAA GCA GAA ACG CAT GCC TGG TTC 1016
Phe Ser Gln Glu Asn Gln Ala Glu Thr His Ala Trp Phe
205 210 215

ACC TCC CGA TTC CTC TAC CAT GTG GCG GGA TTC CTG CTG 1055
Thr Ser Arg Phe Leu Tyr His Val Ala Gly Phe Leu Leu
220 225

CCC ATG CTG GTG ATG GGC TGG TGC TAC GTG GGG GTA GTG 1094
Pro Met Leu Val Met Gly Trp Cys Tyr Val Gly Val Val
230 235 240

CAC AGG TTG CGC CAG GCC CAG CGG CGC CCT CAG CGG CAG 1133
His Arg Leu Arg Gln Ala Gln Arg Arg Pro Gln Arg Gln
245 250 255

5 AAG GCA GTC AGG GTG GCC ATC CTG GTG ACA AGC ATC TTC 1172
Lys Ala Val Arg Val Ala Ile Leu Val Thr Ser Ile Phe
260 265

10 TTC CTC TGC TGG TCA CCC TAC CAC ATC GTC ATC TTC CTG 1211
Phe Leu Cys Trp Ser Pro Tyr His Ile Val Ile Phe Leu
270 275 280

15 GAC ACC CTG GCG AGG CTG AAG GCC GTG GAC AAT ACC TGC 1250
Asp Thr Leu Ala Arg Leu Lys Ala Val Asp Asn Thr Cys
285 290

20 AAG CTG AAT GGC TCT CTC CCC GTG GCC ATC ACC ATG TGT 1289
Lys Leu Asn Gly Ser Leu Pro Val Ala Ile Thr Met Cys
295 300 305

GAG TTC CTG GGC CTG GCC CAC TGC TGC CTC AAC CCC ATG 1328
Glu Phe Leu Gly Leu Ala His Cys Cys Leu Asn Pro Met
310 315 320

25 CTC TAC ACT TTC GCC GGC GTG AAG TTC CGC AGT GAC CTG 1367
Leu Tyr Thr Phe Ala Gly Val Lys Phe Arg Ser Asp Leu
325 330

30 TCG CGG CTC CTG ACG AAG CTG GGC TGT ACC GGC CCT GCC 1406
Ser Arg Leu Leu Thr Lys Leu Gly Cys Thr Gly Pro Ala
335 340 345

35 TCC CTG TGC CAG CTC TTC CCT AGC TGG CGC AGG AGC AGT 1445
Ser Leu Cys Gln Leu Phe Pro Ser Trp Arg Arg Ser Ser
350 355

CTC TCT GAG TCA GAG AAT GCC ACC TCT CTC ACC ACG TTC TA 1486
Leu Ser Glu Ser Glu Asn Ala Thr Ser Leu Thr Thr Phe
360 365 370 372

GGTC CCAGTGTCCC CTTTTATTGC TGCTTTTCCT TGGGGCAGGC 1530

45 AGTGATGCTG GATGCTCCTT CCAACAGGAG CTGGGATCCT AAGGGCTCAC 1580

CGTGGCTAAG AGTGTCCTAG GAGTATCCTC ATTTGGGGTA GCTAGAGGAA 1630

50 CCAACCCCCA TTTCTAGAAC ATCCCGCGGC CGCCAGCACA CTGGAATTC 1679

WHAT IS CLAIMED IS:


1. An antibody that is capable of binding a PF4AR polypeptide.
2. The antibody of claim 1 that does not cross-react with a receptor capable of binding another PF4 superfamily member.
3. The antibody of claim 1 wherein the PF4AR polypeptide is an IL-8 receptor.
4. The antibody of claim 3 wherein the PF4AR polypeptide is an IL-8 type A receptor.
5. The antibody of claim 4 that is a monoclonal antibody.
6. The antibody of claim 4 that has the isotype IgG1.
7. The antibody of claim 1 that neutralizes the activity of a PF4AR polypeptide.
8. The antibody of claim 4 that neutralizes the activity of an IL-8 type A receptor.
9. The antibody of claim 8 that is a monoclonal antibody designated 2A4, having ATCC Deposit No. 11377.
10. The antibody of claim 8 that is a monoclonal antibody designated 9H1, having ATCC Deposit No. 11376.
11. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

12. A composition comprising the antibody of claim 4 and a pharmaceutically acceptable carrier.
13. A composition comprising the antibody of claim 8 and a pharmaceutically acceptable carrier.
14. A method for treating an inflammatory disorder comprising administering to a mammal in need of such treatment an effective amount of the composition of claim 11.
15. The method of claim 14 wherein the mammal is a human.
16. The method of claim 14 wherein the disorder is an inflammatory bowel disease or a chronic inflammation of the lung.
17. The method of claim 14 wherein the composition is administered systemically.
18. A method for treating an inflammatory disorder comprising administering to a mammal in need of such treatment an effective amount of the composition of claim 12.
19. A method for treating an inflammatory disorder comprising administering to a mammal in need of such treatment an effective amount of the composition of claim 13.

ANTIBODIES TO HUMAN PF4A RECEPTOR

Abstract of the Disclosure

cdNAs encoding a class of receptors, including the IL-8 receptors, have been identified in human tissue. Recombinantly produced PF4ARs are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory conditions.



	ATG TCA AAT ATT ACA GAT CCA CAG ATG TGG GAT TTT 86	
	Met Ser Asn Ile Thr Asp Pro Gln Met Trp Asp Phe	
	1 5 10	
5	GAT GAT CTA AAT TTC ACT GGC ATG CCA CCT GCA GAT GAA 125	
	Asp Asp Leu Asn Phe Thr Gly Met Pro Pro Ala Asp Glu	
	15 20 25	
10	GAT TAC AGC CCC TGT ATG CTA GAA ACT GAG ACA CTC AAC 164	
	Asp Tyr Ser Pro Cys Met Leu Glu Thr Glu Thr Leu Asn	
	30 35	
15	AAG TAT GTT GTG ATC ATC GCC TAT GCC CTA GTG TTC CTG 203	
	Lys Tyr Val Val Ile Ile Ala Tyr Ala Leu Val Phe Leu	
	40 45 50	
20	CTG AGC CTG CTG GGA AAC TCC CTG GTG ATG CTG GTC ATC 242	
	Leu Ser Leu Leu Gly Asn Ser Leu Val Met Leu Val Ile	
	55 60	
25	TTA TAC AGC AGG GTC GGC CGC TCC GTC ACT GAT GTC TAC 281	
	Leu Tyr Ser Arg Val Gly Arg Ser Val Thr Asp Val Tyr	
	65 70 75	
30	CTG CTG AAC CTG GCC TTG GCC GAC CTA CTC TTT GCC CTG 320	
	Leu Leu Asn Leu Ala Leu Ala Asp Leu Leu Phe Ala Leu	
	80 85 90	
35	ACC TTG CCC ATC TGG GCC GCC TCC AAG GTG AAT GGC TGG 359	
	Thr Leu Pro Ile Trp Ala Ala Ser Lys Val Asn Gly Trp	
	95 100	
40	ATT TTT GGC ACA TTC CTG TGC AAG GTG GTC TCA CTC CTG 398	
	Ile Phe Gly Thr Phe Leu Cys Lys Val Val Ser Leu Leu	
	105 110 115	
45	AAG GAA GTC AAC TTC TAC AGT GGC ATC CTG CTG TTG GCC 437	
	Lys Glu Val Asn Phe Tyr Ser Gly Ile Leu Leu Leu Ala	
	120 125	
50	TGC ATC AGT GTG GAC CGT TAC CTG GCC ATT GTC CAT GCC 476	
	Cys Ile Ser Val Asp Arg Tyr Leu Ala Ile Val His Ala	
	130 135 140	
55	ACA CGC ACA CTG ACC CAG AAG CGT CAC TTG GTC AAG TTT 515	
	Thr Arg Thr Leu Thr Gln Lys Arg His Leu Val Lys Phe	
	145 150 155	
60	GTT TGT CTT GGC TGC TGG GGA CTG TCT ATG AAT CTG TCC 554	
	Val Cys Leu Gly Cys Trp Gly Leu Ser Met Asn Leu Ser	
	160 165	
65	CTG CCC TTC TTC CTT TTC CGC CAG GCT TAC CAT CCA AAC 593	
	Leu Pro Phe Phe Leu Phe Arg Gln Ala Tyr His Pro Asn	
	170 175 180	
70	AAT TCC AGT CCA GTT TGC TAT GAG GTC CTG GGA AAT GAC 632	

Fig. 2a

Asn Ser Ser Pro Val Cys Tyr Glu Val Leu Gly Asn Asp
185 190

5 ACA GCA AAA TGG CGG ATG GTG TTG CGG ATC CTG CCT CAC 671
Thr Ala Lys Trp Arg Met Val Leu Arg Ile Leu Pro His
195 200 205

10 ACC TTT GGC TTC ATC GTG CCG CTG TTT GTC ATG CTG TTC 710
Thr Phe Gly Phe Ile Val Pro Leu Phe Val Met Leu Phe
210 215 220

15 TGC TAT GGA TTC ACC CTG CGT ACA CTG TTT AAG GCC CAC 749
Cys Tyr Gly Phe Thr Leu Arg Thr Leu Phe Lys Ala His
225 230

ATG GGG CAG AAG CAC CGA GCC ATG AGG GTC ATC TTT GCT 788
Met Gly Gln Lys His Arg Ala Met Arg Val Ile Phe Ala
235 240 245

20 GTC GTC CTC ATC TTC CTG CTT TGC TGG CTG CCC TAC AAC 827
Val Val Leu Ile Phe Leu Leu Cys Trp Leu Pro Tyr Asn
250 255

25 CTG GTC CTG CTG GCA GAC ACC CTC ATG AGG ACC CAG GTG 866
Leu Val Leu Leu Ala Asp Thr Leu Met Arg Thr Gln Val
260 265 270

30 ATC CAG GAG ACC TGT GAG CGC CGC AAC AAC ATC GGC CGG 905
Ile Gln Glu Thr Cys Glu Arg Arg Asn Asn Ile Gly Arg
275 280 285

GCC CTG GAT GCC ACT GAG ATT CTG GGA TTT CTC CAT AGC 944
Ala Leu Asp Ala Thr Glu Ile Leu Gly Phe Leu His Ser
290 295

35 TGC CTC AAC CCC ATC ATC TAC GCC TTC ATC GGC CAA AAT 983
Cys Leu Asn Pro Ile Ile Tyr Ala Phe Ile Gly Gln Asn
300 305 310

40 TTT CGC CAT GGA TTC CTC AAG ATC CTG GCT ATG CAT GGC 1022
Phe Arg His Gly Phe Leu Lys Ile Leu Ala Met His Gly
315 320

45 CTG GTC AGC AAG GAG TTC TTG GCA CGT CAT CGT GTT ACC 1061
Leu Val Ser Lys Glu Phe Leu Ala Arg His Arg Val Thr
325 330 335

50 TCC TAC ACT TCT TCG TCT GTC AAT GTC TCT TCC AAC CTC 1100
Ser Tyr Thr Ser Ser Ser Val Asn Val Ser Ser Asn Leu
340 345 350

TGAAAACCAT CGATGAAGGA ATATCTCTTC TCAGAAGGAA AGAATAACCA 1150

55 ACACCCTGAG GTTGTGTGTG GAAGGTGATC TGGCTCTGGA CAGGCACTAT 1200

CTGGGTTTTG GGGGSACGCT ATAGGATGTG GGGAAAGTTAG GAACTGGTGT 1250

Fig. 2b

5 CTTCAAGGGGC CACACCAACC TTCTGAGGAG CTGTTGAGGT ACCTCCAAGG 1300
 ACCGGCCTTT GCACCTCCAT GGAACGAAG CACCATCATT CCCGTTGAAC 1350
 10 GTCACATCTT TAACCCACTA ACTGGCTAAT TAGCATGGCC ACATCTGAGC 1400
 CCCGAATCTG ACATTAGATG AGAGAACAGG GCTGAAGCTG TGTCTCATG 1450
 15 AGGGCTGGAT GCTCTCGTTG ACCCTCACAG GAGCATCTCC TCAACTCTGA 1500
 GTGTTAAGCG TTGAGCCACC AAGCTGGTGG CTCTGTGTGC TCTGATCCGA 1550
 20 GCTCAGGGGG GTGGTTTTCC CATCTCAGGT GTGTTGCAGT GTCTGCTGGA 1600
 GACATTGAGG CAGGCACTGC CAAAACATCA ACCTGCCAGC TGGCCTTGTG 1650
 25 AGGAGCTGGA AACACATGTT CCCCTTGGGG GTGGTGGATG AACAAAGAGA 1700
 AAGAGGGTTT GGAAGCCAGA TCTATGCCAC AAGAACCCCC TTTACCCCCA 1750
 TGACCAACAT CGCAGACACA TGTGCTGGCC ACCTGCTGAG CCCCAGTGG 1800
 35 AACGAGACAA GCAGCCCTTA GCCCTTCCCC TCTGCAGCTT CCAGGCTGGC 1850
 GTGCAGCATC AGCATCCCTA GAAAGCCATG TGCAGCCACC AGTCCATTGG 1900
 40 GCAGGCAGAT GTTCCTAATA AAGCTTCTGT TCC 1933

Fig. 2c




Figure 3a




Figure 3b

GAATTCAGT GTGCTGGCGG CGCGGCGCAA AGTGACGCCG AGGGCCTGAG 50

TGCTCCAGTA GCCACCGCAT CTGGAGAACC AGCGGTTACC ATG GAG 96
Met Glu
1

GGG ATC AGT ATA TAC ACT TCA GAT AAC TAC ACC GAG GAA 135
Gly Ile Ser Ile Tyr Thr Ser Asp Asn Tyr Thr Glu Glu
5 10 15

ATG GGC TCA GGG GAC TAT GAC TCC ATG AAG GAA CCC TGT 174
Met Gly Ser Gly Asp Tyr Asp Ser Met Lys Glu Pro Cys
20 25

TTC CGT GAA GAA AAT GCT AAT TTC AAT AAA ATC TTC CTG 213
Phe Arg Glu Glu Asn Ala Asn Phe Asn Lys Ile Phe Leu
30 35 40

CCC ACC ATC TAC TCC ATC ATC TTC TTA ACT GGC ATT GTG 252
Pro Thr Ile Tyr Ser Ile Ile Phe Leu Thr Gly Ile Val
45 50

GGC AAT GGA TTG GTC ATC CTG GTC ATG GGT TAC CAG AAG 291
Gly Asn Gly Leu Val Ile Leu Val Met Gly Tyr Gln Lys
55 60 65

AAA CTG AGA AGC ATG ACG GAC AAG TAC AGG CTG CAC CTG 330
Lys Leu Arg Ser Met Thr Asp Lys Tyr Arg Leu His Leu
70 75 80

TCA GTG GCC GAC CTC CTC TTT GTC ATC ACG CTT CCC TTC 369
Ser Val Ala Asp Leu Leu Phe Val Ile Thr Leu Pro Phe
85 90

TGG GCA GTT GAT GCC GTG GCA AAC TGG TAC TTT GGG AAC 408
Trp Ala Val Asp Ala Val Ala Asn Trp Tyr Phe Gly Asn
95 100 105

TTC CTA TGC AAG GCA GTC CAT GTC ATC TAC ACA GTC AAC 447
Phe Leu Cys Lys Ala Val His Val Ile Tyr Thr Val Asn
110 115

CTC TAC AGC AGT GTC CTC ATC CTG GCC TTC ATC AGT CTG 486
Leu Tyr Ser Ser Val Leu Ile Leu Ala Phe Ile Ser Leu
120 125 130

GAC CGC TAC CTG GCC ATC GTC CAC GCC ACC AAC AGT CAG 525
Asp Arg Tyr Leu Ala Ile Val His Ala Thr Asn Ser Gln
135 140 145

AGG CCA AGG AAG CTG TTG GCT GAA AAG GTG GTC TAT GTT 564
Arg Pro Arg Lys Leu Leu Ala Glu Lys Val Val Tyr Val
150 155

GGC GTC TGG ATC CCT GCC CTC CTG CTG ACT ATT CCC GAC 603
Gly Val Trp Ile Pro Ala Leu Leu Leu Thr Ile Pro Asp
160 165 170

Figure 4a

09104053-064498

TTC ATC TTT GCC AAC GTC AGT GAG GCA GAT GAC AGA TAT 642
 Phe Ile Phe Phe Ala Asn Val Ser Glu Ala Asp Asp Arg Tyr
 175 180

ATC TGT GAC CGC TTC TAC CCC AAT GAC TTG TGG GTG GTT 681
 Ile Cys Asp Arg Phe Tyr Pro Asn Asp Leu Trp Val Val
 185 190 195

GTG TTC CAG TTT CAG CAC ATC ATG GTT GGC CTT ATC CTG 720
 Val Phe Gln Phe Gln His Ile Met Val Gly Leu Ile Leu
 200 205 210

CCT GGT ATT GTC ATC CTG TCC TGC TAT TGC ATT ATC ATC 759
 Pro Gly Ile Val Ile Leu Ser Cys Tyr Cys Ile Ile Ile
 215 220

TCC AAG CTG TCA CAC TCC AAG GGC CAC CAG AAG CGC AAG 798
 Ser Lys Leu Ser His Ser Lys Gly His Gln Lys Arg Lys
 225 230 235

GCC CTC AAG ACC ACA GTC ATC CTC ATC CTG GCT TTC TTC 837
 Ala Leu Lys Thr Thr Val Ile Leu Ile Leu Ala Phe Phe
 240 245

GCC TGT TGG CTG CCT TAC TAC ATT GGG ATC AGC ATC GAC 876
 Ala Cys Trp Leu Pro Tyr Tyr Ile Gly Ile Ser Ile Asp
 250 255 260

TCC TTC ATC CTC CTG GAA ATC ATC AAG CAA GGG TGT GAG 915
 Ser Phe Ile Leu Leu Glu Ile Ile Lys Gln Gly Cys Glu
 265 270 275

TTT GAG AAC ACT GTG CAC AAG TGG ATT TCC ATC ACC GAG 954
 Phe Glu Asn Thr Val His Lys Trp Ile Ser Ile Thr Glu
 280 285

GCC CTA GCT TTC TTC CAC TGT TGT CTG AAC CCC ATC CTC 993
 Ala Leu Ala Phe Phe His Cys Cys Leu Asn Pro Ile Leu
 290 295 300

TAT GCT TTC CTT GGA GCC AAA TTT AAA ACC TCT GCC CAG 1032
 Tyr Ala Phe Leu Gly Ala Lys Phe Lys Thr Ser Ala Gln
 305 310

CAC GCA CTC ACC TCT GTG AGC AGA GGG TCC AGC CTC AAG 1071
 His Ala Leu Thr Ser Val Ser Arg Gly Ser Ser Leu Lys
 315 320 325

ATC CTC TCC AAA GGA AAG CGA GGT GGA CAT TCA TCT GTT 1110
 Ile Leu Ser Lys Gly Lys Arg Gly Gly His Ser Ser Val
 330 335 340

TCC ACT GAG TCT GAG TCT TCA AGT TTT CAC TCC AGC TAAC 1150
 Ser Thr Glu Ser Glu Ser Ser Ser Phe His Ser Ser
 345 350 352

ACAGATGTAA AAGACTTTTT TTTATACGAT AAATAACTTT TTTTAAAGTT 1200

Figure 4b

ACACATTTT CAGATATAAA AGACTGACCA ATATTGTACA GTTTTTATTG 1250
 CTTGTGGAT TTTGTCTTG TGTTCTTTA GTTTTGTGA AGTTTAATTG 1300
 ACTTATTTAT ATAAATTTT TTTGTTTCAT ATTGATGTGT GTCTAGGCAG 1350
 GACCTGTGGC CAAGTTCTTA GTTGCTGTAT GTCTCGTGGT AGGACTGTAG 1400
 AAAAGGGAAC TGAACATTCC AGAGCGTGTA GTGAATCACG TAAAGCTAGA 1450
 AATGATCCCC AGCTGTTTAT GCATAGATAA TCTCTCCATT CCCGTGGAAC 1500
 GTTTTTCCTG TTCTTAAGAC GTGATTTTGC TGTAGAAGAT GGCAC TTATA 1550
 ACCAAAGCCC AAAGTGGTAT AGAAATGCTG GTTTTTCAGT TTTCAGGAGT 1600
 GGGTTGATTT CAGCACCTAC AGTGACAGT CTTGTATTAA GTTGTTAATA 1650
 AAAGTACATG TTAAACTTAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1700
 AAAAAAAAAA AAAGCGGCCG CCAGCACACT GGAATTC 1737

Figure 4c

GAATTCCAGT GTGCTGGCGG CCGCCAGTG TGCTGGCGGC GGCAGTTGAG 50

GGAAAGGACA GAGGTTATGA GTGCCTGCAA GAGTGGCAGC CTGGAGTAGA 100

GAAAACACTA AAGGTGGAGT CAAAAGACCT GAGTTCAAGT CCCAGCTCTG 150

CCACTGGTTA GCTGTGGGAT CTCGGAAAAG ACCCAGTGAA AAAAAAAAAA 200

AAAGTGATGA GTTGTGAGGC AGGTCGCGGC CCTACTGCCT CAGGAGACGA 250

TGCGCAGCTC ATTTGCTTAA ATTTGCAGCT GACGGCTGCC ACCTCTCTAG 300

AGGCACCTGG CGGGGAGCCT CTCAACATAA GACAGTGACC AGTCTGGTGA 350

CTCACAGCCG GCACAGCC ATG AAC TAC CCG CTA ACG CTG GAA 392
Met Asn Tyr Pro Leu Thr Leu Glu
1 5

ATG GAC CTC GAG AAC CTG GAG GAC CTG TTC TGG GAA CTG 431
Met Asp Leu Glu Asn Leu Glu Asp Leu Phe Trp Glu Leu
10 15 20

GAC AGA TTG GAC AAC TAT AAC GAC ACC TCC CTG GTG GAA 470
Asp Arg Leu Asp Asn Tyr Asn Asp Thr Ser Leu Val Glu
25 30

AAT CAT CTC TGC CCT GCC ACA GAG GGG CCC CTC ATG GCC 509
Asn His Leu Cys Pro Ala Thr Glu Gly Pro Leu Met Ala
35 40 45

TCC TTC AAG GCC GTG TTC GTG CCC GTG GCC TAC AGC CTC 548
Ser Phe Lys Ala Val Phe Val Pro Val Ala Tyr Ser Leu
50 55 60

ATC TTC CTC CTG GGC GTG ATC GGC AAC GTC CTG GTG CTG 587
Ile Phe Leu Leu Gly Val Ile Gly Asn Val Leu Val Leu
65 70

GTG ATC CTG GAG CGG CAC CGG CAG ACA CGC AGT TCC ACG 626
Val Ile Leu Glu Arg His Arg Gln Thr Arg Ser Ser Thr
75 80 85

GAG ACC TTC CTG TTC CAC CTG GCC GTG GCC GAC CTC CTG 665
Glu Thr Phe Leu Phe His Leu Ala Val Ala Asp Leu Leu
90 95

CTG GTC TTC ATC TTG CCC TTT GCC GTG GCC GAG GGC TCT 704
Leu Val Phe Ile Leu Pro Phe Ala Val Ala Glu Gly Ser
100 105 110

Figure 5a

GTG	GGC	TGG	GTC	CTG	GGG	ACC	TTC	CTC	TGC	AAA	ACT	GTG	743
Val	Gly	Trp	Val	Leu	Gly	Thr	Phe	Leu	Cys	Lys	Thr	Val	
		115					120					125	
ATT	GCC	CTG	CAC	AAA	GTC	AAC	TTC	TAC	TGC	AGC	AGC	CTG	782
Ile	Ala	Leu	His	Lys	Val	Asn	Phe	Tyr	Cys	Ser	Ser	Leu	
			130						135				
CTC	CTG	GCC	TGC	ATC	GCC	GTG	GAC	CGC	TAC	CTG	GCC	ATT	821
Leu	Leu	Ala	Cys	Ile	Ala	Val	Asp	Arg	Tyr	Leu	Ala	Ile	
		140				145					150		
GTC	CAC	GCC	GTC	CAT	GCC	TAC	CGC	CAC	CGC	CGC	CTC	CTC	860
Val	His	Ala	Val	His	Ala	Tyr	Arg	His	Arg	Arg	Leu	Leu	
			155				160						
TCC	ATC	CAC	ATC	ACC	TGT	GGG	ACC	ATC	TGG	CTG	GTG	GGC	899
Ser	Ile	His	Ile	Thr	Cys	Gly	Thr	Ile	Trp	Leu	Val	Gly	
165					170					175			
TTC	CTC	CTT	GCC	TTG	CCA	GAG	ATT	CTC	TTC	GCC	AAA	GTC	938
Phe	Leu	Leu	Ala	Leu	Pro	Glu	Ile	Leu	Phe	Ala	Lys	Val	
		180					185					190	
AGC	CAA	GGC	CAT	CAC	AAC	AAC	TCC	CTG	CCA	CGT	TGC	ACC	977
Ser	Gln	Gly	His	His	Asn	Asn	Ser	Leu	Pro	Arg	Cys	Thr	
				195					200				
TTC	TCC	CAA	GAG	AAC	CAA	GCA	GAA	ACG	CAT	GCC	TGG	TTC	1016
Phe	Ser	Gln	Glu	Asn	Gln	Ala	Glu	Thr	His	Ala	Trp	Phe	
	205				210						215		
ACC	TCC	CGA	TTC	CTC	TAC	CAT	GTG	GCG	GGA	TTC	CTG	CTG	1055
Thr	Ser	Arg	Phe	Leu	Tyr	His	Val	Ala	Gly	Phe	Leu	Leu	
			220					225					
CCC	ATG	CTG	GTG	ATG	GGC	TGG	TGC	TAC	GTG	GGG	GTA	GTG	1094
Pro	Met	Leu	Val	Met	Gly	Trp	Cys	Tyr	Val	Gly	Val	Val	
230					235					240			
CAC	AGG	TTG	CGC	CAG	GCC	CAG	CGG	CGC	CCT	CAG	CGG	CAG	1133
His	Arg	Leu	Arg	Gln	Ala	Gln	Arg	Arg	Pro	Gln	Arg	Gln	
		245				250						255	
AAG	GCA	GTC	AGG	GTG	GCC	ATC	CTG	GTG	ACA	AGC	ATC	TTC	1172
Lys	Ala	Val	Arg	Val	Ala	Ile	Leu	Val	Thr	Ser	Ile	Phe	
				260					265				
TTC	CTC	TGC	TGG	TCA	CCC	TAC	CAC	ATC	GTC	ATC	TTC	CTG	1211
Phe	Leu	Cys	Trp	Ser	Pro	Tyr	His	Ile	Val	Ile	Phe	Leu	
	270					275					280		
GAC	ACC	CTG	GCG	AGG	CTG	AAG	GCC	GTG	GAC	AAT	ACC	TGC	1250
Asp	Thr	Leu	Ala	Arg	Leu	Lys	Ala	Val	Asp	Asn	Thr	Cys	
			285					290					

Figure 5b

AAG CTG AAT GGC TCT CTC CCC GTG GCC ATC ACC ATG TGT 1289
 Lys Leu Asn Gly Ser Leu Pro Val Ala Ile Thr Met Cys
 295 300 305

GAG TTC CTG GGC CTG GCC CAC TGC TGC CTC AAC CCC ATG 1328
 Glu Phe Leu Gly Leu Ala His Cys Cys Leu Asn Pro Met
 310 315 320

CTC TAC ACT TTC GCC GGC GTG AAG TTC CGC AGT GAC CTG 1367
 Leu Tyr Thr Phe Ala Gly Val Lys Phe Arg Ser Asp Leu
 325 330

TCG CGG CTC CTG ACG AAG CTG GGC TGT ACC GGC CCT GCC 1406
 Ser Arg Leu Leu Thr Lys Leu Gly Cys Thr Gly Pro Ala
 335 340 345

TCC CTG TGC CAG CTC TTC CCT AGC TGG CGC AGG AGC AGT 1445
 Ser Leu Cys Gln Leu Phe Pro Ser Trp Arg Arg Ser Ser
 350 355

CTC TCT GAG TCA GAG AAT GCC ACC TCT CTC ACC ACG TTC TA 1486
 Leu Ser Glu Ser Glu Asn Ala Thr Ser Leu Thr Thr Phe
 360 365 370 372

GGTC CCAAGTGCCC CTTTATTGC TGCTTTTCCT TGGGGCAGGC 1530

AGTGATGCTG GATGCTCCTT CCAACAGGAG CTGGGATCCT AAGGGCTCAC 1580

CGTGGCTAAG AGTGTCCTAG GAGTATCCTC ATTIGGGGTA GCTAGAGGAA 1630

CCAACCCCCA TTTCTAGAAC ATCCCGCGGC CGCCAGCACA CTGGAATTC 1679

Figure 5c

$$\text{HOOC}-\text{COOH}$$


7.15.21

→








FIG. 8

A



B







Fig 4



Concentrations of IL8 in Sputum from Patients with Chronic Airway Inflammation and Induced Sputum from Healthy Subjects



COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PF4A RECEPTOR

the specification of which is attached hereto and is amended by preliminary amendment filed herewith.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate have a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):

Priority Claimed
Yes No

Number	Country	Day/Month/Year Filed

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional applications(s) listed below:

Application Ser. No.	Filing Date

I hereby claim the benefit under Title 35, United States Code, §120 of any United States applications(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

08/664,228	6 June 1996	Pending
Application Ser. No.	Filing Date	Status: Patented, Pending, Abandoned
08/076,093	11 June 1993	Patented
Application Ser. No.	Filing Date	Status: Patented, Pending, Abandoned
07/810,782	19 December 1991	Abandoned
Application Ser. No.	Filing Date	Status: Patented, Pending, Abandoned

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Walter E. Buting - Reg. No. 23,092
Ginger R. Dreger - Reg. No. 33,055
Richard B. Love - Reg. No. 34,659
Diane L. Marschang - Reg. No. 35,600
Daryl B. Winter - Reg. No. 32,637
Timothy E. Torchia - Reg. No. 36,700

Jeffrey S. Kubinec - Reg. No. 36,575
Stephen Raines - Reg. No. 25,912
Janet E. Hasak - Reg. No. 28,616
Sean A. Johnston - Reg. No. 35,910
Dennis G. Kleid - Reg. No. 32,037
Wendy M. Lee - Reg. No. P-40,378

Send correspondence to Genentech, Inc.
Attn: Richard B. Love
460 Point San Bruno Boulevard
South San Francisco, CA 94080
Telephone: (415) 225-5530


I hereby declare that all statements made herein of my own knowledge and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from his foreign patent agent as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

Full name of sole or first inventor

James Lee

Inventor's signature



Date

1996 August 22

Residence

705 Shelter Creek Lane, San Bruno, California 94066

Citizenship

U.S.A.


Post Office Address

P.O. Box 5058
South San Francisco, CA 94083

Full name of second joint inventor, if any

William I. Wood

Inventor's signature



Date

8/22/96

Residence

1400 Terrytown Street, San Mateo, California 94402

Citizenship

U.S.A.

Post Office Address

460 Point San Bruno Boulevard
South San Francisco, CA 94080